542	CH_2NH-SO_2CH_3	2-F-phenyl	2-(methylaminosulfonyl)phenyl
543	CH_2NH-SO_2CH_3	2-F-phenyl	1-pyrrolidinocarbonyl
544	CH_2NH-SO_2CH_3	2-F-phenyl	2-(methylsulfonyl)phenyl
545	CH_2NH-SO_2CH_3	2-F-phenyl	4-morpholino
546	CH_2NH-SO_2CH_3	2-F-phenyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
547	CH_2NH-SO_2CH_3	2-F-phenyl	4-morpholinocarbonyl
548	CH_2NH-SO_2CH_3	2-F-phenyl	2-methyl-1-imidazolyl
549	CH_2NH-SO_2CH_3	2-F-phenyl	5-methyl-1-imidazolyl
550	CH_2NH-SO_2CH_3	2-F-phenyl	2-methylsulfonyl-1-imidazolyl
551	CH_2NH-SO_2CH_3	2,6-diF-phenyl	2-(aminosulfonyl)phenyl
552	CH_2NH-SO_2CH_3	2,6-diF-phenyl	2-(methylaminosulfonyl)phenyl
553	CH_2NH-SO_2CH_3	2,6-diF-phenyl	1-pyrrolidinocarbonyl
554	CH_2NH-SO_2CH_3	2,6-diF-phenyl	2-(methylsulfonyl)phenyl
555	CH_2NH-SO_2CH_3	2,6-diF-phenyl	4-morpholino
556	CH_2NH-SO_2CH_3	2,6-diF-phenyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
557	CH_2NH-SO_2CH_3	2,6-diF-phenyl	4-morpholinocarbonyl
558	CH_2NH-SO_2CH_3	2,6-diF-phenyl	2-methyl-1-imidazolyl
559	CH_2NH-SO_2CH_3	2,6-diF-phenyl	5-methyl-1-imidazolyl
560	CH_2NH-SO_2CH_3	2,6-diF-phenyl	2-methylsulfonyl-1-imidazolyl
561	Cl	phenyl	2-(aminosulfonyl)phenyl
562	Cl	phenyl	2-(methylaminosulfonyl)phenyl
563	Cl	phenyl	1-pyrrolidinocarbonyl
564	Cl	phenyl	2-(methylsulfonyl)phenyl
565	Cl	phenyl	4-morpholino
566	Cl	phenyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
567	Cl	phenyl	4-morpholinocarbonyl
568	Cl	phenyl	2-methyl-1-imidazolyl
569	Cl	phenyl	5-methyl-1-imidazolyl
570	Cl	phenyl	2-methylsulfonyl-1-imidazolyl
571	Cl	2-pyridyl	2-(aminosulfonyl)phenyl
572	Cl	2-pyridyl	2-(methylaminosulfonyl)phenyl

573	Cl	2-pyridyl	1-pyrrolidinocarbonyl
574	Cl	2-pyridyl	2-(methylsulfonyl)phenyl
575	Cl	2-pyridyl	4-morpholino
576	Cl	2-pyridyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
577	Cl	2-pyridyl	4-morpholinocarbonyl
578	Cl	2-pyridyl	2-methyl-1-imidazolyl
579	Cl	2-pyridyl	5-methyl-1-imidazolyl
580	Cl	2-pyridyl	2-methylsulfonyl-1-imidazolyl
581	Cl	3-pyridyl	2-(aminosulfonyl)phenyl
582	Cl	3-pyridyl	2-(methylaminosulfonyl)phenyl
583	Cl	3-pyridyl	1-pyrrolidinocarbonyl
584	Cl	3-pyridyl	2-(methylsulfonyl)phenyl
585	Cl	3-pyridyl	4-morpholino
586	Cl	3-pyridyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
587	Cl	3-pyridyl	4-morpholinocarbonyl
588	Cl	3-pyridyl	2-methyl-1-imidazolyl
589	Cl	3-pyridyl	5-methyl-1-imidazolyl
590	Cl	3-pyridyl	2-methylsulfonyl-1-imidazolyl
591	Cl	2-pyrimidyl	2-(aminosulfonyl)phenyl
592	Cl	2-pyrimidyl	2-(methylaminosulfonyl)phenyl
593	Cl	2-pyrimidyl	1-pyrrolidinocarbonyl
594	Cl	2-pyrimidyl	2-(methylsulfonyl)phenyl
595	Cl	2-pyrimidyl	4-morpholino
596	Cl	2-pyrimidyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
597	Cl	2-pyrimidyl	4-morpholinocarbonyl
598	Cl	2-pyrimidyl	2-methyl-1-imidazolyl
599	Cl	2-pyrimidyl	5-methyl-1-imidazolyl
600	Cl	2-pyrimidyl	2-methylsulfonyl-1-imidazolyl
601	Cl	5-pyrimidyl	2-(aminosulfonyl)phenyl
602	Cl	5-pyrimidyl	2-(methylaminosulfonyl)phenyl
603	Cl	5-pyrimidyl	1-pyrrolidinocarbonyl
604	Cl	5-pyrimidyl	2-(methylsulfonyl)phenyl
605	Cl	5-pyrimidyl	4-morpholino
606	Cl	5-pyrimidyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
607	Cl	5-pyrimidyl	4-morpholinocarbonyl
608	Cl	5-pyrimidyl	2-methyl-1-imidazolyl
609	Cl	5-pyrimidyl	5-methyl-1-imidazolyl
610	Cl	5-pyrimidyl	2-methylsulfonyl-1-imidazolyl
611	Cl	2-Cl-phenyl	2-(aminosulfonyl)phenyl
612	Cl	2-Cl-phenyl	2-(methylaminosulfonyl)phenyl
613	Cl	2-Cl-phenyl	1-pyrrolidinocarbonyl
614	Cl	2-Cl-phenyl	2-(methylsulfonyl)phenyl
615	Cl	2-Cl-phenyl	4-morpholino
616	Cl	2-Cl-phenyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
617	Cl	2-Cl-phenyl	4-morpholinocarbonyl
618	Cl	2-Cl-phenyl	2-methyl-1-imidazolyl
619	Cl	2-Cl-phenyl	5-methyl-1-imidazolyl
620	Cl	2-Cl-phenyl	2-methylsulfonyl-1-imidazolyl
621	Cl	2-F-phenyl	2-(aminosulfonyl)phenyl
622	Cl	2-F-phenyl	2-(methylaminosulfonyl)phenyl
623	Cl	2-F-phenyl	1-pyrrolidinocarbonyl
624	Cl	2-F-phenyl	2-(methylsulfonyl)phenyl
625	Cl	2-F-phenyl	4-morpholino
626	Cl	2-F-phenyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
627	Cl	2-F-phenyl	4-morpholinocarbonyl

628	Cl	2-F-phenyl	2-methyl-1-imidazolyl
629	Cl	2-F-phenyl	5-methyl-1-imidazolyl
630	Cl	2-F-phenyl	2-methylsulfonyl-1-imidazolyl
631	Cl	2,6-diF-phenyl	2-(aminosulfonyl)phenyl
632	Cl	2,6-diF-phenyl	2-(methylaminosulfonyl)phenyl
633	Cl	2,6-diF-phenyl	1-pyrrolidinocarbonyl
634	Cl	2,6-diF-phenyl	2-(methylsulfonyl)phenyl
635	Cl	2,6-diF-phenyl	4-morpholino
636	Cl	2,6-diF-phenyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
637	Cl	2,6-diF-phenyl	4-morpholinocarbonyl
638	Cl	2,6-diF-phenyl	2-methyl-1-imidazolyl
639	Cl	2,6-diF-phenyl	5-methyl-1-imidazolyl
640	Cl	2,6-diF-phenyl	2-methylsulfonyl-1-imidazolyl
641	F	phenyl	2-(aminosulfonyl)phenyl
642	F	phenyl	2-(methylaminosulfonyl)phenyl
643	F	phenyl	1-pyrrolidinocarbonyl
644	F	phenyl	2-(methylsulfonyl)phenyl
645	F	phenyl	4-morpholino
646	F	phenyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
647	F	phenyl	4-morpholinocarbonyl
648	F	phenyl	2-methyl-1-imidazolyl
649	F	phenyl	5-methyl-1-imidazolyl
650	F	phenyl	2-methylsulfonyl-1-imidazolyl
651	F	2-pyridyl	2-(aminosulfonyl)phenyl
652	F	2-pyridyl	2-(methylaminosulfonyl)phenyl
653	F	2-pyridyl	1-pyrrolidinocarbonyl
654	F	2-pyridyl	2-(methylsulfonyl)phenyl
655	F	2-pyridyl	4-morpholino
656	F	2-pyridyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
657	F	2-pyridyl	4-morpholinocarbonyl
658	F	2-pyridyl	2-methyl-1-imidazolyl
659	F	2-pyridyl	5-methyl-1-imidazolyl
660	F	2-pyridyl	2-methylsulfonyl-1-imidazolyl
661	F	3-pyridyl	2-(aminosulfonyl)phenyl
662	F	3-pyridyl	2-(methylaminosulfonyl)phenyl
663	F	3-pyridyl	1-pyrrolidinocarbonyl
664	F	3-pyridyl	2-(methylsulfonyl)phenyl
665	F	3-pyridyl	4-morpholino
666	F	3-pyridyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
667	F	3-pyridyl	4-morpholinocarbonyl
668	F	3-pyridyl	2-methyl-1-imidazolyl
669	F	3-pyridyl	5-methyl-1-imidazolyl
670	F	3-pyridyl	2-methylsulfonyl-1-imidazolyl
671	F	2-pyrimidyl	2-(aminosulfonyl)phenyl
672	F	2-pyrimidyl	2-(methylaminosulfonyl)phenyl
673	F	2-pyrimidyl	1-pyrrolidinocarbonyl
674	F	2-pyrimidyl	2-(methylsulfonyl)phenyl
675	F	2-pyrimidyl	4-morpholino
676	F	2-pyrimidyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
677	F	2-pyrimidyl	4-morpholinocarbonyl
678	F	2-pyrimidyl	2-methyl-1-imidazolyl
679	F	2-pyrimidyl	5-methyl-1-imidazolyl
680	F	2-pyrimidyl	2-methylsulfonyl-1-imidazolyl
681	F	5-pyrimidyl	2-(aminosulfonyl)phenyl
682	F	5-pyrimidyl	2-(methylaminosulfonyl)phenyl

683	F	5-pyrimidyl	1-pyrrolidinocarbonyl
684	F	5-pyrimidyl	2-(methylsulfonyl)phenyl
685	F	5-pyrimidyl	4-morpholino
686	F	5-pyrimidyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
687	F	5-pyrimidyl	4-morpholinocarbonyl
688	F	5-pyrimidyl	2-methyl-1-imidazolyl
689	F	5-pyrimidyl	5-methyl-1-imidazolyl
690	F	5-pyrimidyl	2-methylsulfonyl-1-imidazolyl
691	F	2-Cl-phenyl	2-(aminosulfonyl)phenyl
692	F	2-Cl-phenyl	2-(methylaminosulfonyl)phenyl
693	F	2-Cl-phenyl	1-pyrrolidinocarbonyl
694	F	2-Cl-phenyl	2-(methylsulfonyl)phenyl
695	F	2-Cl-phenyl	4-morpholino
696	F	2-Cl-phenyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
697	F	2-Cl-phenyl	4-morpholinocarbonyl
698	F	2-Cl-phenyl	2-methyl-1-imidazolyl
699	F	2-Cl-phenyl	5-methyl-1-imidazolyl
700	F	2-Cl-phenyl	2-methylsulfonyl-1-imidazolyl
701	F	2-F-phenyl	2-(aminosulfonyl)phenyl
702	F	2-F-phenyl	2-(methylaminosulfonyl)phenyl
703	F	2-F-phenyl	1-pyrrolidinocarbonyl
704	F	2-F-phenyl	2-(methylsulfonyl)phenyl
705	F	2-F-phenyl	4-morpholino
706	F	2-F-phenyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
707	F	2-F-phenyl	4-morpholinocarbonyl
708	F	2-F-phenyl	2-methyl-1-imidazolyl
709	F	2-F-phenyl	5-methyl-1-imidazolyl
710	F	2-F-phenyl	2-methylsulfonyl-1-imidazolyl
711	F	2,6-diF-phenyl	2-(aminosulfonyl)phenyl
712	F	2,6-diF-phenyl	2-(methylaminosulfonyl)phenyl
713	F	2,6-diF-phenyl	1-pyrrolidinocarbonyl
714	F	2,6-diF-phenyl	2-(methylsulfonyl)phenyl
715	F	2,6-diF-phenyl	4-morpholino
716	F	2,6-diF-phenyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
717	F	2,6-diF-phenyl	4-morpholinocarbonyl
718	F	2,6-diF-phenyl	2-methyl-1-imidazolyl
719	F	2,6-diF-phenyl	5-methyl-1-imidazolyl
720	F	2,6-diF-phenyl	2-methylsulfonyl-1-imidazolyl
721	CO_2CH_3	phenyl	2-(aminosulfonyl)phenyl
722	CO_2CH_3	phenyl	2-(methylaminosulfonyl)phenyl
723	CO_2CH_3	phenyl	1-pyrrolidinocarbonyl
724	CO_2CH_3	phenyl	2-(methylsulfonyl)phenyl
725	CO_2CH_3	phenyl	4-morpholino
726	CO_2CH_3	phenyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
727	CO_2CH_3	phenyl	4-morpholinocarbonyl
728	CO_2CH_3	phenyl	2-methyl-1-imidazolyl
729	CO_2CH_3	phenyl	5-methyl-1-imidazolyl
730	CO_2CH_3	phenyl	2-methylsulfonyl-1-imidazolyl
731	CO_2CH_3	2-pyridyl	2-(aminosulfonyl)phenyl
732	CO_2CH_3	2-pyridyl	2-(methylaminosulfonyl)phenyl
733	CO_2CH_3	2-pyridyl	1-pyrrolidinocarbonyl
734	CO_2CH_3	2-pyridyl	2-(methylsulfonyl)phenyl
735	CO_2CH_3	2-pyridyl	4-morpholino

736	CO_2CH_3	2-pyridyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
737	CO_2CH_3	2-pyridyl	4-morpholinocarbonyl
738	CO_2CH_3	2-pyridyl	2-methyl-1-imidazolyl
739	CO_2CH_3	2-pyridyl	5-methyl-1-imidazolyl
740	CO_2CH_3	2-pyridyl	2-methylsulfonyl-1-imidazolyl
741	CO_2CH_3	3-pyridyl	2-(aminosulfonyl)phenyl
742	CO_2CH_3	3-pyridyl	2-(methylaminosulfonyl)phenyl
743	CO_2CH_3	3-pyridyl	1-pyrrolidinocarbonyl
744	CO_2CH_3	3-pyridyl	2-(methylsulfonyl)phenyl
745	CO_2CH_3	3-pyridyl	4-morpholino
746	CO_2CH_3	3-pyridyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
747	CO_2CH_3	3-pyridyl	4-morpholinocarbonyl
748	CO_2CH_3	3-pyridyl	2-methyl-1-imidazolyl
749	CO_2CH_3	3-pyridyl	5-methyl-1-imidazolyl
750	CO_2CH_3	3-pyridyl	2-methylsulfonyl-1-imidazolyl
751	CO_2CH_3	2-pyrimidyl	2-(aminosulfonyl)phenyl
752	CO_2CH_3	2-pyrimidyl	2-(methylaminosulfonyl)phenyl
753	CO_2CH_3	2-pyrimidyl	1-pyrrolidinocarbonyl
754	CO_2CH_3	2-pyrimidyl	2-(methylsulfonyl)phenyl
755	CO_2CH_3	2-pyrimidyl	4-morpholino
756	CO_2CH_3	2-pyrimidyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
757	CO_2CH_3	2-pyrimidyl	4-morpholinocarbonyl
758	CO_2CH_3	2-pyrimidyl	2-methyl-1-imidazolyl
759	CO_2CH_3	2-pyrimidyl	5-methyl-1-imidazolyl
760	CO_2CH_3	2-pyrimidyl	2-methylsulfonyl-1-imidazolyl
761	CO_2CH_3	5-pyrimidyl	2-(aminosulfonyl)phenyl
762	CO_2CH_3	5-pyrimidyl	2-(methylaminosulfonyl)phenyl
763	CO_2CH_3	5-pyrimidyl	1-pyrrolidinocarbonyl
764	CO_2CH_3	5-pyrimidyl	2-(methylsulfonyl)phenyl
765	CO_2CH_3	5-pyrimidyl	4-morpholino
766	CO_2CH_3	5-pyrimidyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
767	CO_2CH_3	5-pyrimidyl	4-morpholinocarbonyl
768	CO_2CH_3	5-pyrimidyl	2-methyl-1-imidazolyl
769	CO_2CH_3	5-pyrimidyl	5-methyl-1-imidazolyl
770	CO_2CH_3	5-pyrimidyl	2-methylsulfonyl-1-imidazolyl
771	CO_2CH_3	2-Cl-phenyl	2-(aminosulfonyl)phenyl
772	CO_2CH_3	2-Cl-phenyl	2-(methylaminosulfonyl)phenyl
773	CO_2CH_3	2-Cl-phenyl	1-pyrrolidinocarbonyl
774	CO_2CH_3	2-Cl-phenyl	2-(methylsulfonyl)phenyl
775	CO_2CH_3	2-Cl-phenyl	4-morpholino
776	CO_2CH_3	2-Cl-phenyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
777	CO_2CH_3	2-Cl-phenyl	4-morpholinocarbonyl
778	CO_2CH_3	2-Cl-phenyl	2-methyl-1-imidazolyl
779	CO_2CH_3	2-Cl-phenyl	5-methyl-1-imidazolyl
780	CO_2CH_3	2-Cl-phenyl	2-methylsulfonyl-1-imidazolyl
781	CO_2CH_3	2-F-phenyl	2-(aminosulfonyl)phenyl
782	CO_2CH_3	2-F-phenyl	2-(methylaminosulfonyl)phenyl
783	CO_2CH_3	2-F-phenyl	1-pyrrolidinocarbonyl

784	CO_2CH_3	2-F-phenyl	2-(methylsulfonyl)phenyl
785	CO_2CH_3	2-F-phenyl	4-morpholino
786	CO_2CH_3	2-F-phenyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
787	CO_2CH_3	2-F-phenyl	4-morpholinocarbonyl
788	CO_2CH_3	2-F-phenyl	2-methyl-1-imidazolyl
789	CO_2CH_3	2-F-phenyl	5-methyl-1-imidazolyl
790	CO_2CH_3	2-F-phenyl	2-methylsulfonyl-1-imidazolyl
791	CO_2CH_3	2,6-diF-phenyl	2-(aminosulfonyl)phenyl
792	CO_2CH_3	2,6-diF-phenyl	2-(methylaminosulfonyl)phenyl
793	CO_2CH_3	2,6-diF-phenyl	1-pyrrolidinocarbonyl
794	CO_2CH_3	2,6-diF-phenyl	2-(methylsulfonyl)phenyl
795	CO_2CH_3	2,6-diF-phenyl	4-morpholino
796	CO_2CH_3	2,6-diF-phenyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
797	CO_2CH_3	2,6-diF-phenyl	4-morpholinocarbonyl
798	CO_2CH_3	2,6-diF-phenyl	2-methyl-1-imidazolyl
799	CO_2CH_3	2,6-diF-phenyl	5-methyl-1-imidazolyl
800	CO_2CH_3	2,6-diF-phenyl	2-methylsulfonyl-1-imidazolyl
801	CH_2OCH_3	phenyl	2-(aminosulfonyl)phenyl
802	CH_2OCH_3	phenyl	2-(methylaminosulfonyl)phenyl
803	CH_2OCH_3	phenyl	1-pyrrolidinocarbonyl
804	CH_2OCH_3	phenyl	2-(methylsulfonyl)phenyl
805	CH_2OCH_3	phenyl	4-morpholino
806	CH_2OCH_3	phenyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
807	CH_2OCH_3	phenyl	4-morpholinocarbonyl
808	CH_2OCH_3	phenyl	2-methyl-1-imidazolyl
809	CH_2OCH_3	phenyl	5-methyl-1-imidazolyl
810	CH_2OCH_3	phenyl	2-methylsulfonyl-1-imidazolyl
811	CH_2OCH_3	2-pyridyl	2-(aminosulfonyl)phenyl
812	CH_2OCH_3	2-pyridyl	2-(methylaminosulfonyl)phenyl
813	CH_2OCH_3	2-pyridyl	1-pyrrolidinocarbonyl
814	CH_2OCH_3	2-pyridyl	2-(methylsulfonyl)phenyl
815	CH_2OCH_3	2-pyridyl	4-morpholino
816	CH_2OCH_3	2-pyridyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
817	CH_2OCH_3	2-pyridyl	4-morpholinocarbonyl
818	CH_2OCH_3	2-pyridyl	2-methyl-1-imidazolyl
819	CH_2OCH_3	2-pyridyl	5-methyl-1-imidazolyl
820	CH_2OCH_3	2-pyridyl	2-methylsulfonyl-1-imidazolyl
821	CH_2OCH_3	3-pyridyl	2-(aminosulfonyl)phenyl
822	CH_2OCH_3	3-pyridyl	2-(methylaminosulfonyl)phenyl
823	CH_2OCH_3	3-pyridyl	1-pyrrolidinocarbonyl
824	CH_2OCH_3	3-pyridyl	2-(methylsulfonyl)phenyl
825	CH_2OCH_3	3-pyridyl	4-morpholino
826	CH_2OCH_3	3-pyridyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
827	CH_2OCH_3	3-pyridyl	4-morpholinocarbonyl
828	CH_2OCH_3	3-pyridyl	2-methyl-1-imidazolyl
829	CH_2OCH_3	3-pyridyl	5-methyl-1-imidazolyl
830	CH_2OCH_3	3-pyridyl	2-methylsulfonyl-1-imidazolyl
831	CH_2OCH_3	2-pyrimidyl	2-(aminosulfonyl)phenyl

832	CH_2OCH_3	2-pyrimidyl	2-(methylaminosulfonyl)phenyl
833	CH_2OCH_3	2-pyrimidyl	1-pyrrolidinocarbonyl
834	CH_2OCH_3	2-pyrimidyl	2-(methylsulfonyl)phenyl
835	CH_2OCH_3	2-pyrimidyl	4-morpholino
836	CH_2OCH_3	2-pyrimidyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
837	CH_2OCH_3	2-pyrimidyl	4-morpholinocarbonyl
838	CH_2OCH_3	2-pyrimidyl	2-methyl-1-imidazolyl
839	CH_2OCH_3	2-pyrimidyl	5-methyl-1-imidazolyl
840	CH_2OCH_3	2-pyrimidyl	2-methylsulfonyl-1-imidazolyl
841	CH_2OCH_3	5-pyrimidyl	2-(aminosulfonyl)phenyl
842	CH_2OCH_3	5-pyrimidyl	2-(methylaminosulfonyl)phenyl
843	CH_2OCH_3	5-pyrimidyl	1-pyrrolidinocarbonyl
844	CH_2OCH_3	5-pyrimidyl	2-(methylsulfonyl)phenyl
845	CH_2OCH_3	5-pyrimidyl	4-morpholino
846	CH_2OCH_3	5-pyrimidyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
847	CH_2OCH_3	5-pyrimidyl	4-morpholinocarbonyl
848	CH_2OCH_3	5-pyrimidyl	2-methyl-1-imidazolyl
849	CH_2OCH_3	5-pyrimidyl	5-methyl-1-imidazolyl
850	CH_2OCH_3	5-pyrimidyl	2-methylsulfonyl-1-imidazolyl
851	CH_2OCH_3	2-Cl-phenyl	2-(aminosulfonyl)phenyl
852	CH_2OCH_3	2-Cl-phenyl	2-(methylaminosulfonyl)phenyl
853	CH_2OCH_3	2-Cl-phenyl	1-pyrrolidinocarbonyl
854	CH_2OCH_3	2-Cl-phenyl	2-(methylsulfonyl)phenyl
855	CH_2OCH_3	2-Cl-phenyl	4-morpholino
856	CH_2OCH_3	2-Cl-phenyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
857	CH_2OCH_3	2-Cl-phenyl	4-morpholinocarbonyl
858	CH_2OCH_3	2-Cl-phenyl	2-methyl-1-imidazolyl
859	CH_2OCH_3	2-Cl-phenyl	5-methyl-1-imidazolyl
860	CH_2OCH_3	2-Cl-phenyl	2-methylsulfonyl-1-imidazolyl
861	CH_2OCH_3	2-F-phenyl	2-(aminosulfonyl)phenyl
862	CH_2OCH_3	2-F-phenyl	2-(methylaminosulfonyl)phenyl
863	CH_2OCH_3	2-F-phenyl	1-pyrrolidinocarbonyl
864	CH_2OCH_3	2-F-phenyl	2-(methylsulfonyl)phenyl
865	CH_2OCH_3	2-F-phenyl	4-morpholino
866	CH_2OCH_3	2-F-phenyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
867	CH_2OCH_3	2-F-phenyl	4-morpholinocarbonyl
868	CH_2OCH_3	2-F-phenyl	2-methyl-1-imidazolyl
869	CH_2OCH_3	2-F-phenyl	5-methyl-1-imidazolyl
870	CH_2OCH_3	2-F-phenyl	2-methylsulfonyl-1-imidazolyl
871	CH_2OCH_3	2,6-diF-phenyl	2-(aminosulfonyl)phenyl
872	CH_2OCH_3	2,6-diF-phenyl	2-(methylaminosulfonyl)phenyl
873	CH_2OCH_3	2,6-diF-phenyl	1-pyrrolidinocarbonyl
874	CH_2OCH_3	2,6-diF-phenyl	2-(methylsulfonyl)phenyl
875	CH_2OCH_3	2,6-diF-phenyl	4-morpholino
876	CH_2OCH_3	2,6-diF-phenyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
877	CH_2OCH_3	2,6-diF-phenyl	4-morpholinocarbonyl
878	CH_2OCH_3	2,6-diF-phenyl	2-methyl-1-imidazolyl
879	CH_2OCH_3	2,6-diF-phenyl	5-methyl-1-imidazolyl

880	CH_2OCH_3	2,6-diF-phenyl	2-methylsulfonyl-1-imidazolyl
881	$CONH_2$	phenyl	2-(aminosulfonyl)phenyl
882	$CONH_2$	phenyl	2-(methylaminosulfonyl)phenyl
883	$CONH_2$	phenyl	1-pyrrolidinocarbonyl
884	$CONH_2$	phenyl	2-(methylsulfonyl)phenyl
885	$CONH_2$	phenyl	4-morpholino
886	$CONH_2$	phenyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
887	$CONH_2$	phenyl	4-morpholinocarbonyl
888	$CONH_2$	phenyl	2-methyl-1-imidazolyl
889	$CONH_2$	phenyl	5-methyl-1-imidazolyl
890	$CONH_2$	phenyl	2-methylsulfonyl-1-imidazolyl
891	$CONH_2$	2-pyridyl	2-(aminosulfonyl)phenyl
892	$CONH_2$	2-pyridyl	2-(methylaminosulfonyl)phenyl
893	$CONH_2$	2-pyridyl	1-pyrrolidinocarbonyl
894	$CONH_2$	2-pyridyl	2-(methylsulfonyl)phenyl
895	$CONH_2$	2-pyridyl	4-morpholino
896	$CONH_2$	2-pyridyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
897	$CONH_2$	2-pyridyl	4-morpholinocarbonyl
898	$CONH_2$	2-pyridyl	2-methyl-1-imidazolyl
899	$CONH_2$	2-pyridyl	5-methyl-1-imidazolyl
900	$CONH_2$	2-pyridyl	2-methylsulfonyl-1-imidazolyl
901	$CONH_2$	3-pyridyl	2-(aminosulfonyl)phenyl
902	$CONH_2$	3-pyridyl	2-(methylaminosulfonyl)phenyl
903	$CONH_2$	3-pyridyl	1-pyrrolidinocarbonyl
904	$CONH_2$	3-pyridyl	2-(methylsulfonyl)phenyl
905	$CONH_2$	3-pyridyl	4-morpholino
906	$CONH_2$	3-pyridyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
907	$CONH_2$	3-pyridyl	4-morpholinocarbonyl
908	$CONH_2$	3-pyridyl	2-methyl-1-imidazolyl
909	$CONH_2$	3-pyridyl	5-methyl-1-imidazolyl
910	$CONH_2$	3-pyridyl	2-methylsulfonyl-1-imidazolyl
911	$CONH_2$	2-pyrimidyl	2-(aminosulfonyl)phenyl
912	$CONH_2$	2-pyrimidyl	2-(methylaminosulfonyl)phenyl
913	$CONH_2$	2-pyrimidyl	1-pyrrolidinocarbonyl
914	$CONH_2$	2-pyrimidyl	2-(methylsulfonyl)phenyl
915	$CONH_2$	2-pyrimidyl	4-morpholino
916	$CONH_2$	2-pyrimidyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
917	$CONH_2$	2-pyrimidyl	4-morpholinocarbonyl
918	$CONH_2$	2-pyrimidyl	2-methyl-1-imidazolyl
919	$CONH_2$	2-pyrimidyl	5-methyl-1-imidazolyl
920	$CONH_2$	2-pyrimidyl	2-methylsulfonyl-1-imidazolyl
921	$CONH_2$	5-pyrimidyl	2-(aminosulfonyl)phenyl
922	$CONH_2$	5-pyrimidyl	2-(methylaminosulfonyl)phenyl
923	$CONH_2$	5-pyrimidyl	1-pyrrolidinocarbonyl
924	$CONH_2$	5-pyrimidyl	2-(methylsulfonyl)phenyl
925	$CONH_2$	5-pyrimidyl	4-morpholino
926	$CONH_2$	5-pyrimidyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
927	$CONH_2$	5-pyrimidyl	4-morpholinocarbonyl

928	$CONH_2$	5-pyrimidyl	2-methyl-1-imidazolyl
929	$CONH_2$	5-pyrimidyl	5-methyl-1-imidazolyl
930	$CONH_2$	5-pyrimidyl	2-methylsulfonyl-1-imidazolyl
931	$CONH_2$	2-Cl-phenyl	2-(aminosulfonyl)phenyl
932	$CONH_2$	2-Cl-phenyl	2-(methylaminosulfonyl)phenyl
933	$CONH_2$	2-Cl-phenyl	1-pyrrolidinocarbonyl
934	$CONH_2$	2-Cl-phenyl	2-(methylsulfonyl)phenyl
935	$CONH_2$	2-Cl-phenyl	4-morpholino
936	$CONH_2$	2-Cl-phenyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
937	$CONH_2$	2-Cl-phenyl	4-morpholinocarbonyl
938	$CONH_2$	2-Cl-phenyl	2-methyl-1-imidazolyl
939	$CONH_2$	2-Cl-phenyl	5-methyl-1-imidazolyl
940	$CONH_2$	2-Cl-phenyl	2-methylsulfonyl-1-imidazolyl
941	$CONH_2$	2-F-phenyl	2-(aminosulfonyl)phenyl
942	$CONH_2$	2-F-phenyl	2-(methylaminosulfonyl)phenyl
943	$CONH_2$	2-F-phenyl	1-pyrrolidinocarbonyl
944	$CONH_2$	2-F-phenyl	2-(methylsulfonyl)phenyl
945	$CONH_2$	2-F-phenyl	4-morpholino
946	$CONH_2$	2-F-phenyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
947	$CONH_2$	2-F-phenyl	4-morpholinocarbonyl
948	$CONH_2$	2-F-phenyl	2-methyl-1-imidazolyl
949	$CONH_2$	2-F-phenyl	5-methyl-1-imidazolyl
950	$CONH_2$	2-F-phenyl	2-methylsulfonyl-1-imidazolyl
951	$CONH_2$	2,6-diF-phenyl	2-(aminosulfonyl)phenyl
952	$CONH_2$	2,6-diF-phenyl	2-(methylaminosulfonyl)phenyl
953	$CONH_2$	2,6-diF-phenyl	1-pyrrolidinocarbonyl
954	$CONH_2$	2,6-diF-phenyl	2-(methylsulfonyl)phenyl
955	$CONH_2$	2,6-diF-phenyl	4-morpholino
956	$CONH_2$	2,6-diF-phenyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
957	$CONH_2$	2,6-diF-phenyl	4-morpholinocarbonyl
958	$CONH_2$	2,6-diF-phenyl	2-methyl-1-imidazolyl
959	$CONH_2$	2,6-diF-phenyl	5-methyl-1-imidazolyl
960	$CONH_2$	2,6-diF-phenyl	2-methylsulfonyl-1-imidazolyl

Table 7




R1a
S
N
H
N
A
B
O
Cl
F
NH2
k
l
m
n


R1a
S
N
H
N
A
B
O
Cl
F
H3CO
NH2
o
p
q


R1a
O
N
H
N
A
B
O
Cl
F
H3CO
NH2
r
s
t


u
v
w
x
y
z
aa
bb
cc
dd


ee


ff


gg


hh


ii


jj


kk


ll


mm


nn



oo



pp



qq



rr



ss



tt



uu



vv

Ex #	R^{1a}	A	B
1	CH_3	phenyl	2-(aminosulfonyl)phenyl
2	CH_3	phenyl	2-(methylaminosulfonyl)phenyl
3	CH_3	phenyl	1-pyrrolidinocarbonyl
4	CH_3	phenyl	2-(methylsulfonyl)phenyl
5	CH_3	phenyl	4-morpholino
6	CH_3	phenyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
7	CH_3	phenyl	4-morpholinocarbonyl
8	CH_3	phenyl	2-methyl-1-imidazolyl
9	CH_3	phenyl	5-methyl-1-imidazolyl
10	CH_3	phenyl	2-methylsulfonyl-1-imidazolyl
11	CH_3	2-pyridyl	2-(aminosulfonyl)phenyl
12	CH_3	2-pyridyl	2-(methylaminosulfonyl)phenyl
13	CH_3	2-pyridyl	1-pyrrolidinocarbonyl
14	CH_3	2-pyridyl	2-(methylsulfonyl)phenyl
15	CH_3	2-pyridyl	4-morpholino
16	CH_3	2-pyridyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
17	CH_3	2-pyridyl	4-morpholinocarbonyl
18	CH_3	2-pyridyl	2-methyl-1-imidazolyl
19	CH_3	2-pyridyl	5-methyl-1-imidazolyl
20	CH_3	2-pyridyl	2-methylsulfonyl-1-imidazolyl
21	CH_3	3-pyridyl	2-(aminosulfonyl)phenyl
22	CH_3	3-pyridyl	2-(methylaminosulfonyl)phenyl
23	CH_3	3-pyridyl	1-pyrrolidinocarbonyl
24	CH_3	3-pyridyl	2-(methylsulfonyl)phenyl
25	CH_3	3-pyridyl	4-morpholino

26	CH_3	3-pyridyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
27	CH_3	3-pyridyl	4-morpholinocarbonyl
28	CH_3	3-pyridyl	2-methyl-1-imidazolyl
29	CH_3	3-pyridyl	5-methyl-1-imidazolyl
30	CH_3	3-pyridyl	2-methylsulfonyl-1-imidazolyl
31	CH_3	2-pyrimidyl	2-(aminosulfonyl)phenyl
32	CH_3	2-pyrimidyl	2-(methylaminosulfonyl)phenyl
33	CH_3	2-pyrimidyl	1-pyrrolidinocarbonyl
34	CH_3	2-pyrimidyl	2-(methylsulfonyl)phenyl
35	CH_3	2-pyrimidyl	4-morpholino
36	CH_3	2-pyrimidyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
37	CH_3	2-pyrimidyl	4-morpholinocarbonyl
38	CH_3	2-pyrimidyl	2-methyl-1-imidazolyl
39	CH_3	2-pyrimidyl	5-methyl-1-imidazolyl
40	CH_3	2-pyrimidyl	2-methylsulfonyl-1-imidazolyl
41	CH_3	5-pyrimidyl	2-(aminosulfonyl)phenyl
42	CH_3	5-pyrimidyl	2-(methylaminosulfonyl)phenyl
43	CH_3	5-pyrimidyl	1-pyrrolidinocarbonyl
44	CH_3	5-pyrimidyl	2-(methylsulfonyl)phenyl
45	CH_3	5-pyrimidyl	4-morpholino
46	CH_3	5-pyrimidyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
47	CH_3	5-pyrimidyl	4-morpholinocarbonyl
48	CH_3	5-pyrimidyl	2-methyl-1-imidazolyl
49	CH_3	5-pyrimidyl	5-methyl-1-imidazolyl
50	CH_3	5-pyrimidyl	2-methylsulfonyl-1-imidazolyl
51	CH_3	2-Cl-phenyl	2-(aminosulfonyl)phenyl
52	CH_3	2-Cl-phenyl	2-(methylaminosulfonyl)phenyl
53	CH_3	2-Cl-phenyl	1-pyrrolidinocarbonyl
54	CH_3	2-Cl-phenyl	2-(methylsulfonyl)phenyl
55	CH_3	2-Cl-phenyl	4-morpholino
56	CH_3	2-Cl-phenyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
57	CH_3	2-Cl-phenyl	4-morpholinocarbonyl
58	CH_3	2-Cl-phenyl	2-methyl-1-imidazolyl
59	CH_3	2-Cl-phenyl	5-methyl-1-imidazolyl
60	CH_3	2-Cl-phenyl	2-methylsulfonyl-1-imidazolyl
61	CH_3	2-F-phenyl	2-(aminosulfonyl)phenyl
62	CH_3	2-F-phenyl	2-(methylaminosulfonyl)phenyl
63	CH_3	2-F-phenyl	1-pyrrolidinocarbonyl
64	CH_3	2-F-phenyl	2-(methylsulfonyl)phenyl
65	CH_3	2-F-phenyl	4-morpholino
66	CH_3	2-F-phenyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
67	CH_3	2-F-phenyl	4-morpholinocarbonyl
68	CH_3	2-F-phenyl	2-methyl-1-imidazolyl
69	CH_3	2-F-phenyl	5-methyl-1-imidazolyl
70	CH_3	2-F-phenyl	2-methylsulfonyl-1-imidazolyl
71	CH_3	2,6-diF-phenyl	2-(aminosulfonyl)phenyl
72	CH_3	2,6-diF-phenyl	2-(methylaminosulfonyl)phenyl
73	CH_3	2,6-diF-phenyl	1-pyrrolidinocarbonyl

74	CH_3	2,6-diF-phenyl	2-(methylsulfonyl)phenyl
75	CH_3	2,6-diF-phenyl	4-morpholino
76	CH_3	2,6-diF-phenyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
77	CH_3	2,6-diF-phenyl	4-morpholinocarbonyl
78	CH_3	2,6-diF-phenyl	2-methyl-1-imidazolyl
79	CH_3	2,6-diF-phenyl	5-methyl-1-imidazolyl
80	CH_3	2,6-diF-phenyl	2-methylsulfonyl-1-imidazolyl
81	CH_2CH_3	phenyl	2-(aminosulfonyl)phenyl
82	CH_2CH_3	phenyl	2-(methylaminosulfonyl)phenyl
83	CH_2CH_3	phenyl	1-pyrrolidinocarbonyl
84	CH_2CH_3	phenyl	2-(methylsulfonyl)phenyl
85	CH_2CH_3	phenyl	4-morpholino
86	CH_2CH_3	phenyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
87	CH_2CH_3	phenyl	4-morpholinocarbonyl
88	CH_2CH_3	phenyl	2-methyl-1-imidazolyl
89	CH_2CH_3	phenyl	5-methyl-1-imidazolyl
90	CH_2CH_3	phenyl	2-methylsulfonyl-1-imidazolyl
91	CH_2CH_3	2-pyridyl	2-(aminosulfonyl)phenyl
92	CH_2CH_3	2-pyridyl	2-(methylaminosulfonyl)phenyl
93	CH_2CH_3	2-pyridyl	1-pyrrolidinocarbonyl
94	CH_2CH_3	2-pyridyl	2-(methylsulfonyl)phenyl
95	CH_2CH_3	2-pyridyl	4-morpholino
96	CH_2CH_3	2-pyridyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
97	CH_2CH_3	2-pyridyl	4-morpholinocarbonyl
98	CH_2CH_3	2-pyridyl	2-methyl-1-imidazolyl
99	CH_2CH_3	2-pyridyl	5-methyl-1-imidazolyl
100	CH_2CH_3	2-pyridyl	2-methylsulfonyl-1-imidazolyl
101	CH_2CH_3	3-pyridyl	2-(aminosulfonyl)phenyl
102	CH_2CH_3	3-pyridyl	2-(methylaminosulfonyl)phenyl
103	CH_2CH_3	3-pyridyl	1-pyrrolidinocarbonyl
104	CH_2CH_3	3-pyridyl	2-(methylsulfonyl)phenyl
105	CH_2CH_3	3-pyridyl	4-morpholino
106	CH_2CH_3	3-pyridyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
107	CH_2CH_3	3-pyridyl	4-morpholinocarbonyl
108	CH_2CH_3	3-pyridyl	2-methyl-1-imidazolyl
109	CH_2CH_3	3-pyridyl	5-methyl-1-imidazolyl
110	CH_2CH_3	3-pyridyl	2-methylsulfonyl-1-imidazolyl
111	CH_2CH_3	2-pyrimidyl	2-(aminosulfonyl)phenyl
112	CH_2CH_3	2-pyrimidyl	2-(methylaminosulfonyl)phenyl
113	CH_2CH_3	2-pyrimidyl	1-pyrrolidinocarbonyl
114	CH_2CH_3	2-pyrimidyl	2-(methylsulfonyl)phenyl
115	CH_2CH_3	2-pyrimidyl	4-morpholino
116	CH_2CH_3	2-pyrimidyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
117	CH_2CH_3	2-pyrimidyl	4-morpholinocarbonyl
118	CH_2CH_3	2-pyrimidyl	2-methyl-1-imidazolyl
119	CH_2CH_3	2-pyrimidyl	5-methyl-1-imidazolyl
120	CH_2CH_3	2-pyrimidyl	2-methylsulfonyl-1-imidazolyl
121	CH_2CH_3	5-pyrimidyl	2-(aminosulfonyl)phenyl

122	CH_2CH_3	5-pyrimidyl	2-(methylaminosulfonyl)phenyl
123	CH_2CH_3	5-pyrimidyl	1-pyrrolidinocarbonyl
124	CH_2CH_3	5-pyrimidyl	2-(methylsulfonyl)phenyl
125	CH_2CH_3	5-pyrimidyl	4-morpholino
126	CH_2CH_3	5-pyrimidyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
127	CH_2CH_3	5-pyrimidyl	4-morpholinocarbonyl
128	CH_2CH_3	5-pyrimidyl	2-methyl-1-imidazolyl
129	CH_2CH_3	5-pyrimidyl	5-methyl-1-imidazolyl
130	CH_2CH_3	5-pyrimidyl	2-methylsulfonyl-1-imidazolyl
131	CH_2CH_3	2-Cl-phenyl	2-(aminosulfonyl)phenyl
132	CH_2CH_3	2-Cl-phenyl	2-(methylaminosulfonyl)phenyl
133	CH_2CH_3	2-Cl-phenyl	1-pyrrolidinocarbonyl
134	CH_2CH_3	2-Cl-phenyl	2-(methylsulfonyl)phenyl
135	CH_2CH_3	2-Cl-phenyl	4-morpholino
136	CH_2CH_3	2-Cl-phenyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
137	CH_2CH_3	2-Cl-phenyl	4-morpholinocarbonyl
138	CH_2CH_3	2-Cl-phenyl	2-methyl-1-imidazolyl
139	CH_2CH_3	2-Cl-phenyl	5-methyl-1-imidazolyl
140	CH_2CH_3	2-Cl-phenyl	2-methylsulfonyl-1-imidazolyl
141	CH_2CH_3	2-F-phenyl	2-(aminosulfonyl)phenyl
142	CH_2CH_3	2-F-phenyl	2-(methylaminosulfonyl)phenyl
143	CH_2CH_3	2-F-phenyl	1-pyrrolidinocarbonyl
144	CH_2CH_3	2-F-phenyl	2-(methylsulfonyl)phenyl
145	CH_2CH_3	2-F-phenyl	4-morpholino
146	CH_2CH_3	2-F-phenyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
147	CH_2CH_3	2-F-phenyl	4-morpholinocarbonyl
148	CH_2CH_3	2-F-phenyl	2-methyl-1-imidazolyl
149	CH_2CH_3	2-F-phenyl	5-methyl-1-imidazolyl
150	CH_2CH_3	2-F-phenyl	2-methylsulfonyl-1-imidazolyl
151	CH_2CH_3	2,6-diF-phenyl	2-(aminosulfonyl)phenyl
152	CH_2CH_3	2,6-diF-phenyl	2-(methylaminosulfonyl)phenyl
153	CH_2CH_3	2,6-diF-phenyl	1-pyrrolidinocarbonyl
154	CH_2CH_3	2,6-diF-phenyl	2-(methylsulfonyl)phenyl
155	CH_2CH_3	2,6-diF-phenyl	4-morpholino
156	CH_2CH_3	2,6-diF-phenyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
157	CH_2CH_3	2,6-diF-phenyl	4-morpholinocarbonyl
158	CH_2CH_3	2,6-diF-phenyl	2-methyl-1-imidazolyl
159	CH_2CH_3	2,6-diF-phenyl	5-methyl-1-imidazolyl
160	CH_2CH_3	2,6-diF-phenyl	2-methylsulfonyl-1-imidazolyl
161	CF_3	phenyl	2-(aminosulfonyl)phenyl
162	CF_3	phenyl	2-(methylaminosulfonyl)phenyl
163	CF_3	phenyl	1-pyrrolidinocarbonyl
164	CF_3	phenyl	2-(methylsulfonyl)phenyl
165	CF_3	phenyl	4-morpholino
166	CF_3	phenyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
167	CF_3	phenyl	4-morpholinocarbonyl
168	CF_3	phenyl	2-methyl-1-imidazolyl
169	CF_3	phenyl	5-methyl-1-imidazolyl

170	CF_3	phenyl	2-methylsulfonyl-1-imidazolyl
171	CF_3	2-pyridyl	2-(aminosulfonyl)phenyl
172	CF_3	2-pyridyl	2-(methylaminosulfonyl)phenyl
173	CF_3	2-pyridyl	1-pyrrolidinocarbonyl
174	CF_3	2-pyridyl	2-(methylsulfonyl)phenyl
175	CF_3	2-pyridyl	4-morpholino
176	CF_3	2-pyridyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
177	CF_3	2-pyridyl	4-morpholinocarbonyl
178	CF_3	2-pyridyl	2-methyl-1-imidazolyl
179	CF_3	2-pyridyl	5-methyl-1-imidazolyl
180	CF_3	2-pyridyl	2-methylsulfonyl-1-imidazolyl
181	CF_3	3-pyridyl	2-(aminosulfonyl)phenyl
182	CF_3	3-pyridyl	2-(methylaminosulfonyl)phenyl
183	CF_3	3-pyridyl	1-pyrrolidinocarbonyl
184	CF_3	3-pyridyl	2-(methylsulfonyl)phenyl
185	CF_3	3-pyridyl	4-morpholino
186	CF_3	3-pyridyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
187	CF_3	3-pyridyl	4-morpholinocarbonyl
188	CF_3	3-pyridyl	2-methyl-1-imidazolyl
189	CF_3	3-pyridyl	5-methyl-1-imidazolyl
190	CF_3	3-pyridyl	2-methylsulfonyl-1-imidazolyl
191	CF_3	2-pyrimidyl	2-(aminosulfonyl)phenyl
192	CF_3	2-pyrimidyl	2-(methylaminosulfonyl)phenyl
193	CF_3	2-pyrimidyl	1-pyrrolidinocarbonyl
194	CF_3	2-pyrimidyl	2-(methylsulfonyl)phenyl
195	CF_3	2-pyrimidyl	4-morpholino
196	CF_3	2-pyrimidyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
197	CF_3	2-pyrimidyl	4-morpholinocarbonyl
198	CF_3	2-pyrimidyl	2-methyl-1-imidazolyl
199	CF_3	2-pyrimidyl	5-methyl-1-imidazolyl
200	CF_3	2-pyrimidyl	2-methylsulfonyl-1-imidazolyl
201	CF_3	5-pyrimidyl	2-(aminosulfonyl)phenyl
202	CF_3	5-pyrimidyl	2-(methylaminosulfonyl)phenyl
203	CF_3	5-pyrimidyl	1-pyrrolidinocarbonyl
204	CF_3	5-pyrimidyl	2-(methylsulfonyl)phenyl
205	CF_3	5-pyrimidyl	4-morpholino
206	CF_3	5-pyrimidyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
207	CF_3	5-pyrimidyl	4-morpholinocarbonyl
208	CF_3	5-pyrimidyl	2-methyl-1-imidazolyl
209	CF_3	5-pyrimidyl	5-methyl-1-imidazolyl
210	CF_3	5-pyrimidyl	2-methylsulfonyl-1-imidazolyl
211	CF_3	2-Cl-phenyl	2-(aminosulfonyl)phenyl
212	CF_3	2-Cl-phenyl	2-(methylaminosulfonyl)phenyl
213	CF_3	2-Cl-phenyl	1-pyrrolidinocarbonyl
214	CF_3	2-Cl-phenyl	2-(methylsulfonyl)phenyl
215	CF_3	2-Cl-phenyl	4-morpholino
216	CF_3	2-Cl-phenyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
217	CF_3	2-Cl-phenyl	4-morpholinocarbonyl

218	CF_3	2-Cl-phenyl	2-methyl-1-imidazolyl
219	CF_3	2-Cl-phenyl	5-methyl-1-imidazolyl
220	CF_3	2-Cl-phenyl	2-methylsulfonyl-1-imidazolyl
221	CF_3	2-F-phenyl	2-(aminosulfonyl)phenyl
222	CF_3	2-F-phenyl	2-(methylaminosulfonyl)phenyl
223	CF_3	2-F-phenyl	1-pyrrolidinocarbonyl
224	CF_3	2-F-phenyl	2-(methylsulfonyl)phenyl
225	CF_3	2-F-phenyl	4-morpholino
226	CF_3	2-F-phenyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
227	CF_3	2-F-phenyl	4-morpholinocarbonyl
228	CF_3	2-F-phenyl	2-methyl-1-imidazolyl
229	CF_3	2-F-phenyl	5-methyl-1-imidazolyl
230	CF_3	2-F-phenyl	2-methylsulfonyl-1-imidazolyl
231	CF_3	2,6-diF-phenyl	2-(aminosulfonyl)phenyl
232	CF_3	2,6-diF-phenyl	2-(methylaminosulfonyl)phenyl
233	CF_3	2,6-diF-phenyl	1-pyrrolidinocarbonyl
234	CF_3	2,6-diF-phenyl	2-(methylsulfonyl)phenyl
235	CF_3	2,6-diF-phenyl	4-morpholino
236	CF_3	2,6-diF-phenyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
237	CF_3	2,6-diF-phenyl	4-morpholinocarbonyl
238	CF_3	2,6-diF-phenyl	2-methyl-1-imidazolyl
239	CF_3	2,6-diF-phenyl	5-methyl-1-imidazolyl
240	CF_3	2,6-diF-phenyl	2-methylsulfonyl-1-imidazolyl
241	SCH_3	phenyl	2-(aminosulfonyl)phenyl
242	SCH_3	phenyl	2-(methylaminosulfonyl)phenyl
243	SCH_3	phenyl	1-pyrrolidinocarbonyl
244	SCH_3	phenyl	2-(methylsulfonyl)phenyl
245	SCH_3	phenyl	4-morpholino
246	SCH_3	phenyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
247	SCH_3	phenyl	4-morpholinocarbonyl
248	SCH_3	phenyl	2-methyl-1-imidazolyl
249	SCH_3	phenyl	5-methyl-1-imidazolyl
250	SCH_3	phenyl	2-methylsulfonyl-1-imidazolyl
251	SCH_3	2-pyridyl	2-(aminosulfonyl)phenyl
252	SCH_3	2-pyridyl	2-(methylaminosulfonyl)phenyl
253	SCH_3	2-pyridyl	1-pyrrolidinocarbonyl
254	SCH_3	2-pyridyl	2-(methylsulfonyl)phenyl
255	SCH_3	2-pyridyl	4-morpholino
256	SCH_3	2-pyridyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
257	SCH_3	2-pyridyl	4-morpholinocarbonyl
258	SCH_3	2-pyridyl	2-methyl-1-imidazolyl
259	SCH_3	2-pyridyl	5-methyl-1-imidazolyl
260	SCH_3	2-pyridyl	2-methylsulfonyl-1-imidazolyl
261	SCH_3	3-pyridyl	2-(aminosulfonyl)phenyl
262	SCH_3	3-pyridyl	2-(methylaminosulfonyl)phenyl
263	SCH_3	3-pyridyl	1-pyrrolidinocarbonyl
264	SCH_3	3-pyridyl	2-(methylsulfonyl)phenyl
265	SCH_3	3-pyridyl	4-morpholino

266	SCH_3	3-pyridyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
267	SCH_3	3-pyridyl	4-morpholinocarbonyl
268	SCH_3	3-pyridyl	2-methyl-1-imidazolyl
269	SCH_3	3-pyridyl	5-methyl-1-imidazolyl
270	SCH_3	3-pyridyl	2-methylsulfonyl-1-imidazolyl
271	SCH_3	2-pyrimidyl	2-(aminosulfonyl)phenyl
272	SCH_3	2-pyrimidyl	2-(methylaminosulfonyl)phenyl
273	SCH_3	2-pyrimidyl	1-pyrrolidinocarbonyl
274	SCH_3	2-pyrimidyl	2-(methylsulfonyl)phenyl
275	SCH_3	2-pyrimidyl	4-morpholino
276	SCH_3	2-pyrimidyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
277	SCH_3	2-pyrimidyl	4-morpholinocarbonyl
278	SCH_3	2-pyrimidyl	2-methyl-1-imidazolyl
279	SCH_3	2-pyrimidyl	5-methyl-1-imidazolyl
280	SCH_3	2-pyrimidyl	2-methylsulfonyl-1-imidazolyl
281	SCH_3	5-pyrimidyl	2-(aminosulfonyl)phenyl
282	SCH_3	5-pyrimidyl	2-(methylaminosulfonyl)phenyl
283	SCH_3	5-pyrimidyl	1-pyrrolidinocarbonyl
284	SCH_3	5-pyrimidyl	2-(methylsulfonyl)phenyl
285	SCH_3	5-pyrimidyl	4-morpholino
286	SCH_3	5-pyrimidyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
287	SCH_3	5-pyrimidyl	4-morpholinocarbonyl
288	SCH_3	5-pyrimidyl	2-methyl-1-imidazolyl
289	SCH_3	5-pyrimidyl	5-methyl-1-imidazolyl
290	SCH_3	5-pyrimidyl	2-methylsulfonyl-1-imidazolyl
291	SCH_3	2-Cl-phenyl	2-(aminosulfonyl)phenyl
292	SCH_3	2-Cl-phenyl	2-(methylaminosulfonyl)phenyl
293	SCH_3	2-Cl-phenyl	1-pyrrolidinocarbonyl
294	SCH_3	2-Cl-phenyl	2-(methylsulfonyl)phenyl
295	SCH_3	2-Cl-phenyl	4-morpholino
296	SCH_3	2-Cl-phenyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
297	SCH_3	2-Cl-phenyl	4-morpholinocarbonyl
298	SCH_3	2-Cl-phenyl	2-methyl-1-imidazolyl
299	SCH_3	2-Cl-phenyl	5-methyl-1-imidazolyl
300	SCH_3	2-Cl-phenyl	2-methylsulfonyl-1-imidazolyl
301	SCH_3	2-F-phenyl	2-(aminosulfonyl)phenyl
302	SCH_3	2-F-phenyl	2-(methylaminosulfonyl)phenyl
303	SCH_3	2-F-phenyl	1-pyrrolidinocarbonyl
304	SCH_3	2-F-phenyl	2-(methylsulfonyl)phenyl
305	SCH_3	2-F-phenyl	4-morpholino
306	SCH_3	2-F-phenyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
307	SCH_3	2-F-phenyl	4-morpholinocarbonyl
308	SCH_3	2-F-phenyl	2-methyl-1-imidazolyl
309	SCH_3	2-F-phenyl	5-methyl-1-imidazolyl
310	SCH_3	2-F-phenyl	2-methylsulfonyl-1-imidazolyl
311	SCH_3	2,6-diF-phenyl	2-(aminosulfonyl)phenyl
312	SCH_3	2,6-diF-phenyl	2-(methylaminosulfonyl)phenyl
313	SCH_3	2,6-diF-phenyl	1-pyrrolidinocarbonyl

314	SCH_3	2,6-diF-phenyl	2-(methylsulfonyl)phenyl
315	SCH_3	2,6-diF-phenyl	4-morpholino
316	SCH_3	2,6-diF-phenyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
317	SCH_3	2,6-diF-phenyl	4-morpholinocarbonyl
318	SCH_3	2,6-diF-phenyl	2-methyl-1-imidazolyl
319	SCH_3	2,6-diF-phenyl	5-methyl-1-imidazolyl
320	SCH_3	2,6-diF-phenyl	2-methylsulfonyl-1-imidazolyl
321	$SOCH_3$	phenyl	2-(aminosulfonyl)phenyl
322	$SOCH_3$	phenyl	2-(methylaminosulfonyl)phenyl
323	$SOCH_3$	phenyl	1-pyrrolidinocarbonyl
324	$SOCH_3$	phenyl	2-(methylsulfonyl)phenyl
325	$SOCH_3$	phenyl	4-morpholino
326	$SOCH_3$	phenyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
327	$SOCH_3$	phenyl	4-morpholinocarbonyl
328	$SOCH_3$	phenyl	2-methyl-1-imidazolyl
329	$SOCH_3$	phenyl	5-methyl-1-imidazolyl
330	$SOCH_3$	phenyl	2-methylsulfonyl-1-imidazolyl
331	$SOCH_3$	2-pyridyl	2-(aminosulfonyl)phenyl
332	$SOCH_3$	2-pyridyl	2-(methylaminosulfonyl)phenyl
333	$SOCH_3$	2-pyridyl	1-pyrrolidinocarbonyl
334	$SOCH_3$	2-pyridyl	2-(methylsulfonyl)phenyl
335	$SOCH_3$	2-pyridyl	4-morpholino
336	$SOCH_3$	2-pyridyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
337	$SOCH_3$	2-pyridyl	4-morpholinocarbonyl
338	$SOCH_3$	2-pyridyl	2-methyl-1-imidazolyl
339	$SOCH_3$	2-pyridyl	5-methyl-1-imidazolyl
340	$SOCH_3$	2-pyridyl	2-methylsulfonyl-1-imidazolyl
341	$SOCH_3$	3-pyridyl	2-(aminosulfonyl)phenyl
342	$SOCH_3$	3-pyridyl	2-(methylaminosulfonyl)phenyl
343	$SOCH_3$	3-pyridyl	1-pyrrolidinocarbonyl
344	$SOCH_3$	3-pyridyl	2-(methylsulfonyl)phenyl
345	$SOCH_3$	3-pyridyl	4-morpholino
346	$SOCH_3$	3-pyridyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
347	$SOCH_3$	3-pyridyl	4-morpholinocarbonyl
348	$SOCH_3$	3-pyridyl	2-methyl-1-imidazolyl
349	$SOCH_3$	3-pyridyl	5-methyl-1-imidazolyl
350	$SOCH_3$	3-pyridyl	2-methylsulfonyl-1-imidazolyl
351	$SOCH_3$	2-pyrimidyl	2-(aminosulfonyl)phenyl
352	$SOCH_3$	2-pyrimidyl	2-(methylaminosulfonyl)phenyl
353	$SOCH_3$	2-pyrimidyl	1-pyrrolidinocarbonyl
354	$SOCH_3$	2-pyrimidyl	2-(methylsulfonyl)phenyl
355	$SOCH_3$	2-pyrimidyl	4-morpholino
356	$SOCH_3$	2-pyrimidyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
357	$SOCH_3$	2-pyrimidyl	4-morpholinocarbonyl
358	$SOCH_3$	2-pyrimidyl	2-methyl-1-imidazolyl
359	$SOCH_3$	2-pyrimidyl	5-methyl-1-imidazolyl
360	$SOCH_3$	2-pyrimidyl	2-methylsulfonyl-1-imidazolyl
361	$SOCH_3$	5-pyrimidyl	2-(aminosulfonyl)phenyl

362	$SOCH_3$	5-pyrimidyl	2-(methylaminosulfonyl)phenyl
363	$SOCH_3$	5-pyrimidyl	1-pyrrolidinocarbonyl
364	$SOCH_3$	5-pyrimidyl	2-(methylsulfonyl)phenyl
365	$SOCH_3$	5-pyrimidyl	4-morpholino
366	$SOCH_3$	5-pyrimidyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
367	$SOCH_3$	5-pyrimidyl	4-morpholinocarbonyl
368	$SOCH_3$	5-pyrimidyl	2-methyl-1-imidazolyl
369	$SOCH_3$	5-pyrimidyl	5-methyl-1-imidazolyl
370	$SOCH_3$	5-pyrimidyl	2-methylsulfonyl-1-imidazolyl
371	$SOCH_3$	2-Cl-phenyl	2-(aminosulfonyl)phenyl
372	$SOCH_3$	2-Cl-phenyl	2-(methylaminosulfonyl)phenyl
373	$SOCH_3$	2-Cl-phenyl	1-pyrrolidinocarbonyl
374	$SOCH_3$	2-Cl-phenyl	2-(methylsulfonyl)phenyl
375	$SOCH_3$	2-Cl-phenyl	4-morpholino
376	$SOCH_3$	2-Cl-phenyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
377	$SOCH_3$	2-Cl-phenyl	4-morpholinocarbonyl
378	$SOCH_3$	2-Cl-phenyl	2-methyl-1-imidazolyl
379	$SOCH_3$	2-Cl-phenyl	5-methyl-1-imidazolyl
380	$SOCH_3$	2-Cl-phenyl	2-methylsulfonyl-1-imidazolyl
381	$SOCH_3$	2-F-phenyl	2-(aminosulfonyl)phenyl
382	$SOCH_3$	2-F-phenyl	2-(methylaminosulfonyl)phenyl
383	$SOCH_3$	2-F-phenyl	1-pyrrolidinocarbonyl
384	$SOCH_3$	2-F-phenyl	2-(methylsulfonyl)phenyl
385	$SOCH_3$	2-F-phenyl	4-morpholino
386	$SOCH_3$	2-F-phenyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
387	$SOCH_3$	2-F-phenyl	4-morpholinocarbonyl
388	$SOCH_3$	2-F-phenyl	2-methyl-1-imidazolyl
389	$SOCH_3$	2-F-phenyl	5-methyl-1-imidazolyl
390	$SOCH_3$	2-F-phenyl	2-methylsulfonyl-1-imidazolyl
391	$SOCH_3$	2,6-diF-phenyl	2-(aminosulfonyl)phenyl
392	$SOCH_3$	2,6-diF-phenyl	2-(methylaminosulfonyl)phenyl
393	$SOCH_3$	2,6-diF-phenyl	1-pyrrolidinocarbonyl
394	$SOCH_3$	2,6-diF-phenyl	2-(methylsulfonyl)phenyl
395	$SOCH_3$	2,6-diF-phenyl	4-morpholino
396	$SOCH_3$	2,6-diF-phenyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
397	$SOCH_3$	2,6-diF-phenyl	4-morpholinocarbonyl
398	$SOCH_3$	2,6-diF-phenyl	2-methyl-1-imidazolyl
399	$SOCH_3$	2,6-diF-phenyl	5-methyl-1-imidazolyl
400	$SOCH_3$	2,6-diF-phenyl	2-methylsulfonyl-1-imidazolyl
401	SO_2CH_3	phenyl	2-(aminosulfonyl)phenyl
402	SO_2CH_3	phenyl	2-(methylaminosulfonyl)phenyl
403	SO_2CH_3	phenyl	1-pyrrolidinocarbonyl
404	SO_2CH_3	phenyl	2-(methylsulfonyl)phenyl
405	SO_2CH_3	phenyl	4-morpholino
406	SO_2CH_3	phenyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
407	SO_2CH_3	phenyl	4-morpholinocarbonyl
408	SO_2CH_3	phenyl	2-methyl-1-imidazolyl
409	SO_2CH_3	phenyl	5-methyl-1-imidazolyl

410	SO_2CH_3	phenyl	2-methylsulfonyl-1-imidazolyl
411	SO_2CH_3	2-pyridyl	2-(aminosulfonyl)phenyl
412	SO_2CH_3	2-pyridyl	2-(methylaminosulfonyl)phenyl
413	SO_2CH_3	2-pyridyl	1-pyrrolidinocarbonyl
414	SO_2CH_3	2-pyridyl	2-(methylsulfonyl)phenyl
415	SO_2CH_3	2-pyridyl	4-morpholino
416	SO_2CH_3	2-pyridyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
417	SO_2CH_3	2-pyridyl	4-morpholinocarbonyl
418	SO_2CH_3	2-pyridyl	2-methyl-1-imidazolyl
419	SO_2CH_3	2-pyridyl	5-methyl-1-imidazolyl
420	SO_2CH_3	2-pyridyl	2-methylsulfonyl-1-imidazolyl
421	SO_2CH_3	3-pyridyl	2-(aminosulfonyl)phenyl
422	SO_2CH_3	3-pyridyl	2-(methylaminosulfonyl)phenyl
423	SO_2CH_3	3-pyridyl	1-pyrrolidinocarbonyl
424	SO_2CH_3	3-pyridyl	2-(methylsulfonyl)phenyl
425	SO_2CH_3	3-pyridyl	4-morpholino
426	SO_2CH_3	3-pyridyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
427	SO_2CH_3	3-pyridyl	4-morpholinocarbonyl
428	SO_2CH_3	3-pyridyl	2-methyl-1-imidazolyl
429	SO_2CH_3	3-pyridyl	5-methyl-1-imidazolyl
430	SO_2CH_3	3-pyridyl	2-methylsulfonyl-1-imidazolyl
431	SO_2CH_3	2-pyrimidyl	2-(aminosulfonyl)phenyl
432	SO_2CH_3	2-pyrimidyl	2-(methylaminosulfonyl)phenyl
433	SO_2CH_3	2-pyrimidyl	1-pyrrolidinocarbonyl
434	SO_2CH_3	2-pyrimidyl	2-(methylsulfonyl)phenyl
435	SO_2CH_3	2-pyrimidyl	4-morpholino
436	SO_2CH_3	2-pyrimidyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
437	SO_2CH_3	2-pyrimidyl	4-morpholinocarbonyl
438	SO_2CH_3	2-pyrimidyl	2-methyl-1-imidazolyl
439	SO_2CH_3	2-pyrimidyl	5-methyl-1-imidazolyl
440	SO_2CH_3	2-pyrimidyl	2-methylsulfonyl-1-imidazolyl
441	SO_2CH_3	5-pyrimidyl	2-(aminosulfonyl)phenyl
442	SO_2CH_3	5-pyrimidyl	2-(methylaminosulfonyl)phenyl
443	SO_2CH_3	5-pyrimidyl	1-pyrrolidinocarbonyl
444	SO_2CH_3	5-pyrimidyl	2-(methylsulfonyl)phenyl
445	SO_2CH_3	5-pyrimidyl	4-morpholino
446	SO_2CH_3	5-pyrimidyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
447	SO_2CH_3	5-pyrimidyl	4-morpholinocarbonyl
448	SO_2CH_3	5-pyrimidyl	2-methyl-1-imidazolyl
449	SO_2CH_3	5-pyrimidyl	5-methyl-1-imidazolyl
450	SO_2CH_3	5-pyrimidyl	2-methylsulfonyl-1-imidazolyl
451	SO_2CH_3	2-Cl-phenyl	2-(aminosulfonyl)phenyl
452	SO_2CH_3	2-Cl-phenyl	2-(methylaminosulfonyl)phenyl
453	SO_2CH_3	2-Cl-phenyl	1-pyrrolidinocarbonyl
454	SO_2CH_3	2-Cl-phenyl	2-(methylsulfonyl)phenyl
455	SO_2CH_3	2-Cl-phenyl	4-morpholino
456	SO_2CH_3	2-Cl-phenyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
457	SO_2CH_3	2-Cl-phenyl	4-morpholinocarbonyl

458	SO_2CH_3	2-Cl-phenyl	2-methyl-1-imidazolyl
459	SO_2CH_3	2-Cl-phenyl	5-methyl-1-imidazolyl
460	SO_2CH_3	2-Cl-phenyl	2-methylsulfonyl-1-imidazolyl
461	SO_2CH_3	2-F-phenyl	2-(aminosulfonyl)phenyl
462	SO_2CH_3	2-F-phenyl	2-(methylaminosulfonyl)phenyl
463	SO_2CH_3	2-F-phenyl	1-pyrrolidinocarbonyl
464	SO_2CH_3	2-F-phenyl	2-(methylsulfonyl)phenyl
465	SO_2CH_3	2-F-phenyl	4-morpholino
466	SO_2CH_3	2-F-phenyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
467	SO_2CH_3	2-F-phenyl	4-morpholinocarbonyl
468	SO_2CH_3	2-F-phenyl	2-methyl-1-imidazolyl
469	SO_2CH_3	2-F-phenyl	5-methyl-1-imidazolyl
470	SO_2CH_3	2-F-phenyl	2-methylsulfonyl-1-imidazolyl
471	SO_2CH_3	2,6-diF-phenyl	2-(aminosulfonyl)phenyl
472	SO_2CH_3	2,6-diF-phenyl	2-(methylaminosulfonyl)phenyl
473	SO_2CH_3	2,6-diF-phenyl	1-pyrrolidinocarbonyl
474	SO_2CH_3	2,6-diF-phenyl	2-(methylsulfonyl)phenyl
475	SO_2CH_3	2,6-diF-phenyl	4-morpholino
476	SO_2CH_3	2,6-diF-phenyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
477	SO_2CH_3	2,6-diF-phenyl	4-morpholinocarbonyl
478	SO_2CH_3	2,6-diF-phenyl	2-methyl-1-imidazolyl
479	SO_2CH_3	2,6-diF-phenyl	5-methyl-1-imidazolyl
480	SO_2CH_3	2,6-diF-phenyl	2-methylsulfonyl-1-imidazolyl
481	CH_2NH-SO_2CH_3	phenyl	2-(aminosulfonyl)phenyl
482	CH_2NH-SO_2CH_3	phenyl	2-(methylaminosulfonyl)phenyl
483	CH_2NH-SO_2CH_3	phenyl	1-pyrrolidinocarbonyl
484	CH_2NH-SO_2CH_3	phenyl	2-(methylsulfonyl)phenyl
485	CH_2NH-SO_2CH_3	phenyl	4-morpholino
486	CH_2NH-SO_2CH_3	phenyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
487	CH_2NH-SO_2CH_3	phenyl	4-morpholinocarbonyl
488	CH_2NH-SO_2CH_3	phenyl	2-methyl-1-imidazolyl
489	CH_2NH-SO_2CH_3	phenyl	5-methyl-1-imidazolyl
490	CH_2NH-SO_2CH_3	phenyl	2-methylsulfonyl-1-imidazolyl
491	CH_2NH-SO_2CH_3	2-pyridyl	2-(aminosulfonyl)phenyl
492	CH_2NH-SO_2CH_3	2-pyridyl	2-(methylaminosulfonyl)phenyl

493	$CH_2NH-SO_2CH_3$	2-pyridyl	1-pyrrolidinocarbonyl
494	$CH_2NH-SO_2CH_3$	2-pyridyl	2-(methylsulfonyl)phenyl
495	$CH_2NH-SO_2CH_3$	2-pyridyl	4-morpholino
496	$CH_2NH-SO_2CH_3$	2-pyridyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
497	$CH_2NH-SO_2CH_3$	2-pyridyl	4-morpholinocarbonyl
498	$CH_2NH-SO_2CH_3$	2-pyridyl	2-methyl-1-imidazolyl
499	$CH_2NH-SO_2CH_3$	2-pyridyl	5-methyl-1-imidazolyl
500	$CH_2NH-SO_2CH_3$	2-pyridyl	2-methylsulfonyl-1-imidazolyl
501	$CH_2NH-SO_2CH_3$	3-pyridyl	2-(aminosulfonyl)phenyl
502	$CH_2NH-SO_2CH_3$	3-pyridyl	2-(methylaminosulfonyl)phenyl
503	$CH_2NH-SO_2CH_3$	3-pyridyl	1-pyrrolidinocarbonyl
504	$CH_2NH-SO_2CH_3$	3-pyridyl	2-(methylsulfonyl)phenyl
505	$CH_2NH-SO_2CH_3$	3-pyridyl	4-morpholino
506	$CH_2NH-SO_2CH_3$	3-pyridyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
507	$CH_2NH-SO_2CH_3$	3-pyridyl	4-morpholinocarbonyl
508	$CH_2NH-SO_2CH_3$	3-pyridyl	2-methyl-1-imidazolyl
509	$CH_2NH-SO_2CH_3$	3-pyridyl	5-methyl-1-imidazolyl
510	$CH_2NH-SO_2CH_3$	3-pyridyl	2-methylsulfonyl-1-imidazolyl
511	$CH_2NH-SO_2CH_3$	2-pyrimidyl	2-(aminosulfonyl)phenyl
512	$CH_2NH-SO_2CH_3$	2-pyrimidyl	2-(methylaminosulfonyl)phenyl
513	$CH_2NH-SO_2CH_3$	2-pyrimidyl	1-pyrrolidinocarbonyl
514	$CH_2NH-SO_2CH_3$	2-pyrimidyl	2-(methylsulfonyl)phenyl
515	$CH_2NH-SO_2CH_3$	2-pyrimidyl	4-morpholino
516	$CH_2NH-SO_2CH_3$	2-pyrimidyl	2-(1'-CF_3-tetrazol-2-yl)phenyl

517	$CH_2NH-SO_2CH_3$	2-pyrimidyl	4-morpholinocarbonyl
518	$CH_2NH-SO_2CH_3$	2-pyrimidyl	2-methyl-1-imidazolyl
519	$CH_2NH-SO_2CH_3$	2-pyrimidyl	5-methyl-1-imidazolyl
520	$CH_2NH-SO_2CH_3$	2-pyrimidyl	2-methylsulfonyl-1-imidazolyl
521	$CH_2NH-SO_2CH_3$	5-pyrimidyl	2-(aminosulfonyl)phenyl
522	$CH_2NH-SO_2CH_3$	5-pyrimidyl	2-(methylaminosulfonyl)phenyl
523	$CH_2NH-SO_2CH_3$	5-pyrimidyl	1-pyrrolidinocarbonyl
524	$CH_2NH-SO_2CH_3$	5-pyrimidyl	2-(methylsulfonyl)phenyl
525	$CH_2NH-SO_2CH_3$	5-pyrimidyl	4-morpholino
526	$CH_2NH-SO_2CH_3$	5-pyrimidyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
527	$CH_2NH-SO_2CH_3$	5-pyrimidyl	4-morpholinocarbonyl
528	$CH_2NH-SO_2CH_3$	5-pyrimidyl	2-methyl-1-imidazolyl
529	$CH_2NH-SO_2CH_3$	5-pyrimidyl	5-methyl-1-imidazolyl
530	$CH_2NH-SO_2CH_3$	5-pyrimidyl	2-methylsulfonyl-1-imidazolyl
531	$CH_2NH-SO_2CH_3$	2-Cl-phenyl	2-(aminosulfonyl)phenyl
532	$CH_2NH-SO_2CH_3$	2-Cl-phenyl	2-(methylaminosulfonyl)phenyl
533	$CH_2NH-SO_2CH_3$	2-Cl-phenyl	1-pyrrolidinocarbonyl
534	$CH_2NH-SO_2CH_3$	2-Cl-phenyl	2-(methylsulfonyl)phenyl
535	$CH_2NH-SO_2CH_3$	2-Cl-phenyl	4-morpholino
536	$CH_2NH-SO_2CH_3$	2-Cl-phenyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
537	$CH_2NH-SO_2CH_3$	2-Cl-phenyl	4-morpholinocarbonyl
538	$CH_2NH-SO_2CH_3$	2-Cl-phenyl	2-methyl-1-imidazolyl
539	$CH_2NH-SO_2CH_3$	2-Cl-phenyl	5-methyl-1-imidazolyl
540	$CH_2NH-SO_2CH_3$	2-Cl-phenyl	2-methylsulfonyl-1-imidazolyl

541	$CH_2NH-SO_2CH_3$	2-F-phenyl	2-(aminosulfonyl)phenyl
542	$CH_2NH-SO_2CH_3$	2-F-phenyl	2-(methylaminosulfonyl)phenyl
543	$CH_2NH-SO_2CH_3$	2-F-phenyl	1-pyrrolidinocarbonyl
544	$CH_2NH-SO_2CH_3$	2-F-phenyl	2-(methylsulfonyl)phenyl
545	$CH_2NH-SO_2CH_3$	2-F-phenyl	4-morpholino
546	$CH_2NH-SO_2CH_3$	2-F-phenyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
547	$CH_2NH-SO_2CH_3$	2-F-phenyl	4-morpholinocarbonyl
548	$CH_2NH-SO_2CH_3$	2-F-phenyl	2-methyl-1-imidazolyl
549	$CH_2NH-SO_2CH_3$	2-F-phenyl	5-methyl-1-imidazolyl
550	$CH_2NH-SO_2CH_3$	2-F-phenyl	2-methylsulfonyl-1-imidazolyl
551	$CH_2NH-SO_2CH_3$	2,6-diF-phenyl	2-(aminosulfonyl)phenyl
552	$CH_2NH-SO_2CH_3$	2,6-diF-phenyl	2-(methylaminosulfonyl)phenyl
553	$CH_2NH-SO_2CH_3$	2,6-diF-phenyl	1-pyrrolidinocarbonyl
554	$CH_2NH-SO_2CH_3$	2,6-diF-phenyl	2-(methylsulfonyl)phenyl
555	$CH_2NH-SO_2CH_3$	2,6-diF-phenyl	4-morpholino
556	$CH_2NH-SO_2CH_3$	2,6-diF-phenyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
557	$CH_2NH-SO_2CH_3$	2,6-diF-phenyl	4-morpholinocarbonyl
558	$CH_2NH-SO_2CH_3$	2,6-diF-phenyl	2-methyl-1-imidazolyl
559	$CH_2NH-SO_2CH_3$	2,6-diF-phenyl	5-methyl-1-imidazolyl
560	$CH_2NH-SO_2CH_3$	2,6-diF-phenyl	2-methylsulfonyl-1-imidazolyl
561	Cl	phenyl	2-(aminosulfonyl)phenyl
562	Cl	phenyl	2-(methylaminosulfonyl)phenyl
563	Cl	phenyl	1-pyrrolidinocarbonyl
564	Cl	phenyl	2-(methylsulfonyl)phenyl
565	Cl	phenyl	4-morpholino
566	Cl	phenyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
567	Cl	phenyl	4-morpholinocarbonyl
568	Cl	phenyl	2-methyl-1-imidazolyl
569	Cl	phenyl	5-methyl-1-imidazolyl

570	Cl	phenyl	2-methylsulfonyl-1-imidazolyl
571	Cl	2-pyridyl	2-(aminosulfonyl)phenyl
572	Cl	2-pyridyl	2-(methylaminosulfonyl)phenyl
573	Cl	2-pyridyl	1-pyrrolidinocarbonyl
574	Cl	2-pyridyl	2-(methylsulfonyl)phenyl
575	Cl	2-pyridyl	4-morpholino
576	Cl	2-pyridyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
577	Cl	2-pyridyl	4-morpholinocarbonyl
578	Cl	2-pyridyl	2-methyl-1-imidazolyl
579	Cl	2-pyridyl	5-methyl-1-imidazolyl
580	Cl	2-pyridyl	2-methylsulfonyl-1-imidazolyl
581	Cl	3-pyridyl	2-(aminosulfonyl)phenyl
582	Cl	3-pyridyl	2-(methylaminosulfonyl)phenyl
583	Cl	3-pyridyl	1-pyrrolidinocarbonyl
584	Cl	3-pyridyl	2-(methylsulfonyl)phenyl
585	Cl	3-pyridyl	4-morpholino
586	Cl	3-pyridyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
587	Cl	3-pyridyl	4-morpholinocarbonyl
588	Cl	3-pyridyl	2-methyl-1-imidazolyl
589	Cl	3-pyridyl	5-methyl-1-imidazolyl
590	Cl	3-pyridyl	2-methylsulfonyl-1-imidazolyl
591	Cl	2-pyrimidyl	2-(aminosulfonyl)phenyl
592	Cl	2-pyrimidyl	2-(methylaminosulfonyl)phenyl
593	Cl	2-pyrimidyl	1-pyrrolidinocarbonyl
594	Cl	2-pyrimidyl	2-(methylsulfonyl)phenyl
595	Cl	2-pyrimidyl	4-morpholino
596	Cl	2-pyrimidyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
597	Cl	2-pyrimidyl	4-morpholinocarbonyl
598	Cl	2-pyrimidyl	2-methyl-1-imidazolyl
599	Cl	2-pyrimidyl	5-methyl-1-imidazolyl
600	Cl	2-pyrimidyl	2-methylsulfonyl-1-imidazolyl
601	Cl	5-pyrimidyl	2-(aminosulfonyl)phenyl
602	Cl	5-pyrimidyl	2-(methylaminosulfonyl)phenyl
603	Cl	5-pyrimidyl	1-pyrrolidinocarbonyl
604	Cl	5-pyrimidyl	2-(methylsulfonyl)phenyl
605	Cl	5-pyrimidyl	4-morpholino
606	Cl	5-pyrimidyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
607	Cl	5-pyrimidyl	4-morpholinocarbonyl
608	Cl	5-pyrimidyl	2-methyl-1-imidazolyl
609	Cl	5-pyrimidyl	5-methyl-1-imidazolyl
610	Cl	5-pyrimidyl	2-methylsulfonyl-1-imidazolyl
611	Cl	2-Cl-phenyl	2-(aminosulfonyl)phenyl
612	Cl	2-Cl-phenyl	2-(methylaminosulfonyl)phenyl
613	Cl	2-Cl-phenyl	1-pyrrolidinocarbonyl
614	Cl	2-Cl-phenyl	2-(methylsulfonyl)phenyl
615	Cl	2-Cl-phenyl	4-morpholino
616	Cl	2-Cl-phenyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
617	Cl	2-Cl-phenyl	4-morpholinocarbonyl
618	Cl	2-Cl-phenyl	2-methyl-1-imidazolyl
619	Cl	2-Cl-phenyl	5-methyl-1-imidazolyl
620	Cl	2-Cl-phenyl	2-methylsulfonyl-1-imidazolyl
621	Cl	2-F-phenyl	2-(aminosulfonyl)phenyl
622	Cl	2-F-phenyl	2-(methylaminosulfonyl)phenyl
623	Cl	2-F-phenyl	1-pyrrolidinocarbonyl
624	Cl	2-F-phenyl	2-(methylsulfonyl)phenyl

625	Cl	2-F-phenyl	4-morpholino
626	Cl	2-F-phenyl	2-(1'-CF3-tetrazol-2-yl)phenyl
627	Cl	2-F-phenyl	4-morpholinocarbonyl
628	Cl	2-F-phenyl	2-methyl-1-imidazolyl
629	Cl	2-F-phenyl	5-methyl-1-imidazolyl
630	Cl	2-F-phenyl	2-methylsulfonyl-1-imidazolyl
631	Cl	2,6-diF-phenyl	2-(aminosulfonyl)phenyl
632	Cl	2,6-diF-phenyl	2-(methylaminosulfonyl)phenyl
633	Cl	2,6-diF-phenyl	1-pyrrolidinocarbonyl
634	Cl	2,6-diF-phenyl	2-(methylsulfonyl)phenyl
635	Cl	2,6-diF-phenyl	4-morpholino
636	Cl	2,6-diF-phenyl	2-(1'-CF3-tetrazol-2-yl)phenyl
637	Cl	2,6-diF-phenyl	4-morpholinocarbonyl
638	Cl	2,6-diF-phenyl	2-methyl-1-imidazolyl
639	Cl	2,6-diF-phenyl	5-methyl-1-imidazolyl
640	Cl	2,6-diF-phenyl	2-methylsulfonyl-1-imidazolyl
641	F	phenyl	2-(aminosulfonyl)phenyl
642	F	phenyl	2-(methylaminosulfonyl)phenyl
643	F	phenyl	1-pyrrolidinocarbonyl
644	F	phenyl	2-(methylsulfonyl)phenyl
645	F	phenyl	4-morpholino
646	F	phenyl	2-(1'-CF3-tetrazol-2-yl)phenyl
647	F	phenyl	4-morpholinocarbonyl
648	F	phenyl	2-methyl-1-imidazolyl
649	F	phenyl	5-methyl-1-imidazolyl
650	F	phenyl	2-methylsulfonyl-1-imidazolyl
651	F	2-pyridyl	2-(aminosulfonyl)phenyl
652	F	2-pyridyl	2-(methylaminosulfonyl)phenyl
653	F	2-pyridyl	1-pyrrolidinocarbonyl
654	F	2-pyridyl	2-(methylsulfonyl)phenyl
655	F	2-pyridyl	4-morpholino
656	F	2-pyridyl	2-(1'-CF3-tetrazol-2-yl)phenyl
657	F	2-pyridyl	4-morpholinocarbonyl
658	F	2-pyridyl	2-methyl-1-imidazolyl
659	F	2-pyridyl	5-methyl-1-imidazolyl
660	F	2-pyridyl	2-methylsulfonyl-1-imidazolyl
661	F	3-pyridyl	2-(aminosulfonyl)phenyl
662	F	3-pyridyl	2-(methylaminosulfonyl)phenyl
663	F	3-pyridyl	1-pyrrolidinocarbonyl
664	F	3-pyridyl	2-(methylsulfonyl)phenyl
665	F	3-pyridyl	4-morpholino
666	F	3-pyridyl	2-(1'-CF3-tetrazol-2-yl)phenyl
667	F	3-pyridyl	4-morpholinocarbonyl
668	F	3-pyridyl	2-methyl-1-imidazolyl
669	F	3-pyridyl	5-methyl-1-imidazolyl
670	F	3-pyridyl	2-methylsulfonyl-1-imidazolyl
671	F	2-pyrimidyl	2-(aminosulfonyl)phenyl
672	F	2-pyrimidyl	2-(methylaminosulfonyl)phenyl
673	F	2-pyrimidyl	1-pyrrolidinocarbonyl
674	F	2-pyrimidyl	2-(methylsulfonyl)phenyl
675	F	2-pyrimidyl	4-morpholino
676	F	2-pyrimidyl	2-(1'-CF3-tetrazol-2-yl)phenyl
677	F	2-pyrimidyl	4-morpholinocarbonyl
678	F	2-pyrimidyl	2-methyl-1-imidazolyl
679	F	2-pyrimidyl	5-methyl-1-imidazolyl

680	F	2-pyrimidyl	2-methylsulfonyl-1-imidazolyl
681	F	5-pyrimidyl	2-(aminosulfonyl)phenyl
682	F	5-pyrimidyl	2-(methylaminosulfonyl)phenyl
683	F	5-pyrimidyl	1-pyrrolidinocarbonyl
684	F	5-pyrimidyl	2-(methylsulfonyl)phenyl
685	F	5-pyrimidyl	4-morpholino
686	F	5-pyrimidyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
687	F	5-pyrimidyl	4-morpholinocarbonyl
688	F	5-pyrimidyl	2-methyl-1-imidazolyl
689	F	5-pyrimidyl	5-methyl-1-imidazolyl
690	F	5-pyrimidyl	2-methylsulfonyl-1-imidazolyl
691	F	2-Cl-phenyl	2-(aminosulfonyl)phenyl
692	F	2-Cl-phenyl	2-(methylaminosulfonyl)phenyl
693	F	2-Cl-phenyl	1-pyrrolidinocarbonyl
694	F	2-Cl-phenyl	2-(methylsulfonyl)phenyl
695	F	2-Cl-phenyl	4-morpholino
696	F	2-Cl-phenyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
697	F	2-Cl-phenyl	4-morpholinocarbonyl
698	F	2-Cl-phenyl	2-methyl-1-imidazolyl
699	F	2-Cl-phenyl	5-methyl-1-imidazolyl
700	F	2-Cl-phenyl	2-methylsulfonyl-1-imidazolyl
701	F	2-F-phenyl	2-(aminosulfonyl)phenyl
702	F	2-F-phenyl	2-(methylaminosulfonyl)phenyl
703	F	2-F-phenyl	1-pyrrolidinocarbonyl
704	F	2-F-phenyl	2-(methylsulfonyl)phenyl
705	F	2-F-phenyl	4-morpholino
706	F	2-F-phenyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
707	F	2-F-phenyl	4-morpholinocarbonyl
708	F	2-F-phenyl	2-methyl-1-imidazolyl
709	F	2-F-phenyl	5-methyl-1-imidazolyl
710	F	2-F-phenyl	2-methylsulfonyl-1-imidazolyl
711	F	2,6-diF-phenyl	2-(aminosulfonyl)phenyl
712	F	2,6-diF-phenyl	2-(methylaminosulfonyl)phenyl
713	F	2,6-diF-phenyl	1-pyrrolidinocarbonyl
714	F	2,6-diF-phenyl	2-(methylsulfonyl)phenyl
715	F	2,6-diF-phenyl	4-morpholino
716	F	2,6-diF-phenyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
717	F	2,6-diF-phenyl	4-morpholinocarbonyl
718	F	2,6-diF-phenyl	2-methyl-1-imidazolyl
719	F	2,6-diF-phenyl	5-methyl-1-imidazolyl
720	F	2,6-diF-phenyl	2-methylsulfonyl-1-imidazolyl
721	CO_2CH_3	phenyl	2-(aminosulfonyl)phenyl
722	CO_2CH_3	phenyl	2-(methylaminosulfonyl)phenyl
723	CO_2CH_3	phenyl	1-pyrrolidinocarbonyl
724	CO_2CH_3	phenyl	2-(methylsulfonyl)phenyl
725	CO_2CH_3	phenyl	4-morpholino
726	CO_2CH_3	phenyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
727	CO_2CH_3	phenyl	4-morpholinocarbonyl
728	CO_2CH_3	phenyl	2-methyl-1-imidazolyl
729	CO_2CH_3	phenyl	5-methyl-1-imidazolyl
730	CO_2CH_3	phenyl	2-methylsulfonyl-1-imidazolyl
731	CO_2CH_3	2-pyridyl	2-(aminosulfonyl)phenyl
732	CO_2CH_3	2-pyridyl	2-(methylaminosulfonyl)phenyl

733	CO_2CH_3	2-pyridyl	1-pyrrolidinocarbonyl
734	CO_2CH_3	2-pyridyl	2-(methylsulfonyl)phenyl
735	CO_2CH_3	2-pyridyl	4-morpholino
736	CO_2CH_3	2-pyridyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
737	CO_2CH_3	2-pyridyl	4-morpholinocarbonyl
738	CO_2CH_3	2-pyridyl	2-methyl-1-imidazolyl
739	CO_2CH_3	2-pyridyl	5-methyl-1-imidazolyl
740	CO_2CH_3	2-pyridyl	2-methylsulfonyl-1-imidazolyl
741	CO_2CH_3	3-pyridyl	2-(aminosulfonyl)phenyl
742	CO_2CH_3	3-pyridyl	2-(methylaminosulfonyl)phenyl
743	CO_2CH_3	3-pyridyl	1-pyrrolidinocarbonyl
744	CO_2CH_3	3-pyridyl	2-(methylsulfonyl)phenyl
745	CO_2CH_3	3-pyridyl	4-morpholino
746	CO_2CH_3	3-pyridyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
747	CO_2CH_3	3-pyridyl	4-morpholinocarbonyl
748	CO_2CH_3	3-pyridyl	2-methyl-1-imidazolyl
749	CO_2CH_3	3-pyridyl	5-methyl-1-imidazolyl
750	CO_2CH_3	3-pyridyl	2-methylsulfonyl-1-imidazolyl
751	CO_2CH_3	2-pyrimidyl	2-(aminosulfonyl)phenyl
752	CO_2CH_3	2-pyrimidyl	2-(methylaminosulfonyl)phenyl
753	CO_2CH_3	2-pyrimidyl	1-pyrrolidinocarbonyl
754	CO_2CH_3	2-pyrimidyl	2-(methylsulfonyl)phenyl
755	CO_2CH_3	2-pyrimidyl	4-morpholino
756	CO_2CH_3	2-pyrimidyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
757	CO_2CH_3	2-pyrimidyl	4-morpholinocarbonyl
758	CO_2CH_3	2-pyrimidyl	2-methyl-1-imidazolyl
759	CO_2CH_3	2-pyrimidyl	5-methyl-1-imidazolyl
760	CO_2CH_3	2-pyrimidyl	2-methylsulfonyl-1-imidazolyl
761	CO_2CH_3	5-pyrimidyl	2-(aminosulfonyl)phenyl
762	CO_2CH_3	5-pyrimidyl	2-(methylaminosulfonyl)phenyl
763	CO_2CH_3	5-pyrimidyl	1-pyrrolidinocarbonyl
764	CO_2CH_3	5-pyrimidyl	2-(methylsulfonyl)phenyl
765	CO_2CH_3	5-pyrimidyl	4-morpholino
766	CO_2CH_3	5-pyrimidyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
767	CO_2CH_3	5-pyrimidyl	4-morpholinocarbonyl
768	CO_2CH_3	5-pyrimidyl	2-methyl-1-imidazolyl
769	CO_2CH_3	5-pyrimidyl	5-methyl-1-imidazolyl
770	CO_2CH_3	5-pyrimidyl	2-methylsulfonyl-1-imidazolyl
771	CO_2CH_3	2-Cl-phenyl	2-(aminosulfonyl)phenyl
772	CO_2CH_3	2-Cl-phenyl	2-(methylaminosulfonyl)phenyl
773	CO_2CH_3	2-Cl-phenyl	1-pyrrolidinocarbonyl
774	CO_2CH_3	2-Cl-phenyl	2-(methylsulfonyl)phenyl
775	CO_2CH_3	2-Cl-phenyl	4-morpholino
776	CO_2CH_3	2-Cl-phenyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
777	CO_2CH_3	2-Cl-phenyl	4-morpholinocarbonyl
778	CO_2CH_3	2-Cl-phenyl	2-methyl-1-imidazolyl
779	CO_2CH_3	2-Cl-phenyl	5-methyl-1-imidazolyl
780	CO_2CH_3	2-Cl-phenyl	2-methylsulfonyl-1-imidazolyl

781	CO_2CH_3	2-F-phenyl	2-(aminosulfonyl)phenyl
782	CO_2CH_3	2-F-phenyl	2-(methylaminosulfonyl)phenyl
783	CO_2CH_3	2-F-phenyl	1-pyrrolidinocarbonyl
784	CO_2CH_3	2-F-phenyl	2-(methylsulfonyl)phenyl
785	CO_2CH_3	2-F-phenyl	4-morpholino
786	CO_2CH_3	2-F-phenyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
787	CO_2CH_3	2-F-phenyl	4-morpholinocarbonyl
788	CO_2CH_3	2-F-phenyl	2-methyl-1-imidazolyl
789	CO_2CH_3	2-F-phenyl	5-methyl-1-imidazolyl
790	CO_2CH_3	2-F-phenyl	2-methylsulfonyl-1-imidazolyl
791	CO_2CH_3	2,6-diF-phenyl	2-(aminosulfonyl)phenyl
792	CO_2CH_3	2,6-diF-phenyl	2-(methylaminosulfonyl)phenyl
793	CO_2CH_3	2,6-diF-phenyl	1-pyrrolidinocarbonyl
794	CO_2CH_3	2,6-diF-phenyl	2-(methylsulfonyl)phenyl
795	CO_2CH_3	2,6-diF-phenyl	4-morpholino
796	CO_2CH_3	2,6-diF-phenyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
797	CO_2CH_3	2,6-diF-phenyl	4-morpholinocarbonyl
798	CO_2CH_3	2,6-diF-phenyl	2-methyl-1-imidazolyl
799	CO_2CH_3	2,6-diF-phenyl	5-methyl-1-imidazolyl
800	CO_2CH_3	2,6-diF-phenyl	2-methylsulfonyl-1-imidazolyl
801	CH_2OCH_3	phenyl	2-(aminosulfonyl)phenyl
802	CH_2OCH_3	phenyl	2-(methylaminosulfonyl)phenyl
803	CH_2OCH_3	phenyl	1-pyrrolidinocarbonyl
804	CH_2OCH_3	phenyl	2-(methylsulfonyl)phenyl
805	CH_2OCH_3	phenyl	4-morpholino
806	CH_2OCH_3	phenyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
807	CH_2OCH_3	phenyl	4-morpholinocarbonyl
808	CH_2OCH_3	phenyl	2-methyl-1-imidazolyl
809	CH_2OCH_3	phenyl	5-methyl-1-imidazolyl
810	CH_2OCH_3	phenyl	2-methylsulfonyl-1-imidazolyl
811	CH_2OCH_3	2-pyridyl	2-(aminosulfonyl)phenyl
812	CH_2OCH_3	2-pyridyl	2-(methylaminosulfonyl)phenyl
813	CH_2OCH_3	2-pyridyl	1-pyrrolidinocarbonyl
814	CH_2OCH_3	2-pyridyl	2-(methylsulfonyl)phenyl
815	CH_2OCH_3	2-pyridyl	4-morpholino
816	CH_2OCH_3	2-pyridyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
817	CH_2OCH_3	2-pyridyl	4-morpholinocarbonyl
818	CH_2OCH_3	2-pyridyl	2-methyl-1-imidazolyl
819	CH_2OCH_3	2-pyridyl	5-methyl-1-imidazolyl
820	CH_2OCH_3	2-pyridyl	2-methylsulfonyl-1-imidazolyl
821	CH_2OCH_3	3-pyridyl	2-(aminosulfonyl)phenyl
822	CH_2OCH_3	3-pyridyl	2-(methylaminosulfonyl)phenyl
823	CH_2OCH_3	3-pyridyl	1-pyrrolidinocarbonyl
824	CH_2OCH_3	3-pyridyl	2-(methylsulfonyl)phenyl
825	CH_2OCH_3	3-pyridyl	4-morpholino
826	CH_2OCH_3	3-pyridyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
827	CH_2OCH_3	3-pyridyl	4-morpholinocarbonyl
828	CH_2OCH_3	3-pyridyl	2-methyl-1-imidazolyl

829	CH_2OCH_3	3-pyridyl	5-methyl-1-imidazolyl
830	CH_2OCH_3	3-pyridyl	2-methylsulfonyl-1-imidazolyl
831	CH_2OCH_3	2-pyrimidyl	2-(aminosulfonyl)phenyl
832	CH_2OCH_3	2-pyrimidyl	2-(methylaminosulfonyl)phenyl
833	CH_2OCH_3	2-pyrimidyl	1-pyrrolidinocarbonyl
834	CH_2OCH_3	2-pyrimidyl	2-(methylsulfonyl)phenyl
835	CH_2OCH_3	2-pyrimidyl	4-morpholino
836	CH_2OCH_3	2-pyrimidyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
837	CH_2OCH_3	2-pyrimidyl	4-morpholinocarbonyl
838	CH_2OCH_3	2-pyrimidyl	2-methyl-1-imidazolyl
839	CH_2OCH_3	2-pyrimidyl	5-methyl-1-imidazolyl
840	CH_2OCH_3	2-pyrimidyl	2-methylsulfonyl-1-imidazolyl
841	CH_2OCH_3	5-pyrimidyl	2-(aminosulfonyl)phenyl
842	CH_2OCH_3	5-pyrimidyl	2-(methylaminosulfonyl)phenyl
843	CH_2OCH_3	5-pyrimidyl	1-pyrrolidinocarbonyl
844	CH_2OCH_3	5-pyrimidyl	2-(methylsulfonyl)phenyl
845	CH_2OCH_3	5-pyrimidyl	4-morpholino
846	CH_2OCH_3	5-pyrimidyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
847	CH_2OCH_3	5-pyrimidyl	4-morpholinocarbonyl
848	CH_2OCH_3	5-pyrimidyl	2-methyl-1-imidazolyl
849	CH_2OCH_3	5-pyrimidyl	5-methyl-1-imidazolyl
850	CH_2OCH_3	5-pyrimidyl	2-methylsulfonyl-1-imidazolyl
851	CH_2OCH_3	2-Cl-phenyl	2-(aminosulfonyl)phenyl
852	CH_2OCH_3	2-Cl-phenyl	2-(methylaminosulfonyl)phenyl
853	CH_2OCH_3	2-Cl-phenyl	1-pyrrolidinocarbonyl
854	CH_2OCH_3	2-Cl-phenyl	2-(methylsulfonyl)phenyl
855	CH_2OCH_3	2-Cl-phenyl	4-morpholino
856	CH_2OCH_3	2-Cl-phenyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
857	CH_2OCH_3	2-Cl-phenyl	4-morpholinocarbonyl
858	CH_2OCH_3	2-Cl-phenyl	2-methyl-1-imidazolyl
859	CH_2OCH_3	2-Cl-phenyl	5-methyl-1-imidazolyl
860	CH_2OCH_3	2-Cl-phenyl	2-methylsulfonyl-1-imidazolyl
861	CH_2OCH_3	2-F-phenyl	2-(aminosulfonyl)phenyl
862	CH_2OCH_3	2-F-phenyl	2-(methylaminosulfonyl)phenyl
863	CH_2OCH_3	2-F-phenyl	1-pyrrolidinocarbonyl
864	CH_2OCH_3	2-F-phenyl	2-(methylsulfonyl)phenyl
865	CH_2OCH_3	2-F-phenyl	4-morpholino
866	CH_2OCH_3	2-F-phenyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
867	CH_2OCH_3	2-F-phenyl	4-morpholinocarbonyl
868	CH_2OCH_3	2-F-phenyl	2-methyl-1-imidazolyl
869	CH_2OCH_3	2-F-phenyl	5-methyl-1-imidazolyl
870	CH_2OCH_3	2-F-phenyl	2-methylsulfonyl-1-imidazolyl
871	CH_2OCH_3	2,6-diF-phenyl	2-(aminosulfonyl)phenyl
872	CH_2OCH_3	2,6-diF-phenyl	2-(methylaminosulfonyl)phenyl
873	CH_2OCH_3	2,6-diF-phenyl	1-pyrrolidinocarbonyl
874	CH_2OCH_3	2,6-diF-phenyl	2-(methylsulfonyl)phenyl
875	CH_2OCH_3	2,6-diF-phenyl	4-morpholino
876	CH_2OCH_3	2,6-diF-phenyl	2-(1'-CF_3-tetrazol-2-yl)phenyl

877	CH_2OCH_3	2,6-diF-phenyl	4-morpholinocarbonyl
878	CH_2OCH_3	2,6-diF-phenyl	2-methyl-1-imidazolyl
879	CH_2OCH_3	2,6-diF-phenyl	5-methyl-1-imidazolyl
880	CH_2OCH_3	2,6-diF-phenyl	2-methylsulfonyl-1-imidazolyl
881	$CONH_2$	phenyl	2-(aminosulfonyl)phenyl
882	$CONH_2$	phenyl	2-(methylaminosulfonyl)phenyl
883	$CONH_2$	phenyl	1-pyrrolidinocarbonyl
884	$CONH_2$	phenyl	2-(methylsulfonyl)phenyl
885	$CONH_2$	phenyl	4-morpholino
886	$CONH_2$	phenyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
887	$CONH_2$	phenyl	4-morpholinocarbonyl
888	$CONH_2$	phenyl	2-methyl-1-imidazolyl
889	$CONH_2$	phenyl	5-methyl-1-imidazolyl
890	$CONH_2$	phenyl	2-methylsulfonyl-1-imidazolyl
891	$CONH_2$	2-pyridyl	2-(aminosulfonyl)phenyl
892	$CONH_2$	2-pyridyl	2-(methylaminosulfonyl)phenyl
893	$CONH_2$	2-pyridyl	1-pyrrolidinocarbonyl
894	$CONH_2$	2-pyridyl	2-(methylsulfonyl)phenyl
895	$CONH_2$	2-pyridyl	4-morpholino
896	$CONH_2$	2-pyridyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
897	$CONH_2$	2-pyridyl	4-morpholinocarbonyl
898	$CONH_2$	2-pyridyl	2-methyl-1-imidazolyl
899	$CONH_2$	2-pyridyl	5-methyl-1-imidazolyl
900	$CONH_2$	2-pyridyl	2-methylsulfonyl-1-imidazolyl
901	$CONH_2$	3-pyridyl	2-(aminosulfonyl)phenyl
902	$CONH_2$	3-pyridyl	2-(methylaminosulfonyl)phenyl
903	$CONH_2$	3-pyridyl	1-pyrrolidinocarbonyl
904	$CONH_2$	3-pyridyl	2-(methylsulfonyl)phenyl
905	$CONH_2$	3-pyridyl	4-morpholino
906	$CONH_2$	3-pyridyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
907	$CONH_2$	3-pyridyl	4-morpholinocarbonyl
908	$CONH_2$	3-pyridyl	2-methyl-1-imidazolyl
909	$CONH_2$	3-pyridyl	5-methyl-1-imidazolyl
910	$CONH_2$	3-pyridyl	2-methylsulfonyl-1-imidazolyl
911	$CONH_2$	2-pyrimidyl	2-(aminosulfonyl)phenyl
912	$CONH_2$	2-pyrimidyl	2-(methylaminosulfonyl)phenyl
913	$CONH_2$	2-pyrimidyl	1-pyrrolidinocarbonyl
914	$CONH_2$	2-pyrimidyl	2-(methylsulfonyl)phenyl
915	$CONH_2$	2-pyrimidyl	4-morpholino
916	$CONH_2$	2-pyrimidyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
917	$CONH_2$	2-pyrimidyl	4-morpholinocarbonyl
918	$CONH_2$	2-pyrimidyl	2-methyl-1-imidazolyl
919	$CONH_2$	2-pyrimidyl	5-methyl-1-imidazolyl
920	$CONH_2$	2-pyrimidyl	2-methylsulfonyl-1-imidazolyl
921	$CONH_2$	5-pyrimidyl	2-(aminosulfonyl)phenyl
922	$CONH_2$	5-pyrimidyl	2-(methylaminosulfonyl)phenyl
923	$CONH_2$	5-pyrimidyl	1-pyrrolidinocarbonyl
924	$CONH_2$	5-pyrimidyl	2-(methylsulfonyl)phenyl

925	$CONH_2$	5-pyrimidyl	4-morpholino
926	$CONH_2$	5-pyrimidyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
927	$CONH_2$	5-pyrimidyl	4-morpholinocarbonyl
928	$CONH_2$	5-pyrimidyl	2-methyl-1-imidazolyl
929	$CONH_2$	5-pyrimidyl	5-methyl-1-imidazolyl
930	$CONH_2$	5-pyrimidyl	2-methylsulfonyl-1-imidazolyl
931	$CONH_2$	2-Cl-phenyl	2-(aminosulfonyl)phenyl
932	$CONH_2$	2-Cl-phenyl	2-(methylaminosulfonyl)phenyl
933	$CONH_2$	2-Cl-phenyl	1-pyrrolidinocarbonyl
934	$CONH_2$	2-Cl-phenyl	2-(methylsulfonyl)phenyl
935	$CONH_2$	2-Cl-phenyl	4-morpholino
936	$CONH_2$	2-Cl-phenyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
937	$CONH_2$	2-Cl-phenyl	4-morpholinocarbonyl
938	$CONH_2$	2-Cl-phenyl	2-methyl-1-imidazolyl
939	$CONH_2$	2-Cl-phenyl	5-methyl-1-imidazolyl
940	$CONH_2$	2-Cl-phenyl	2-methylsulfonyl-1-imidazolyl
941	$CONH_2$	2-F-phenyl	2-(aminosulfonyl)phenyl
942	$CONH_2$	2-F-phenyl	2-(methylaminosulfonyl)phenyl
943	$CONH_2$	2-F-phenyl	1-pyrrolidinocarbonyl
944	$CONH_2$	2-F-phenyl	2-(methylsulfonyl)phenyl
945	$CONH_2$	2-F-phenyl	4-morpholino
946	$CONH_2$	2-F-phenyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
947	$CONH_2$	2-F-phenyl	4-morpholinocarbonyl
948	$CONH_2$	2-F-phenyl	2-methyl-1-imidazolyl
949	$CONH_2$	2-F-phenyl	5-methyl-1-imidazolyl
950	$CONH_2$	2-F-phenyl	2-methylsulfonyl-1-imidazolyl
951	$CONH_2$	2,6-diF-phenyl	2-(aminosulfonyl)phenyl
952	$CONH_2$	2,6-diF-phenyl	2-(methylaminosulfonyl)phenyl
953	$CONH_2$	2,6-diF-phenyl	1-pyrrolidinocarbonyl
954	$CONH_2$	2,6-diF-phenyl	2-(methylsulfonyl)phenyl
955	$CONH_2$	2,6-diF-phenyl	4-morpholino
956	$CONH_2$	2,6-diF-phenyl	2-(1'-CF_3-tetrazol-2-yl)phenyl
957	$CONH_2$	2,6-diF-phenyl	4-morpholinocarbonyl
958	$CONH_2$	2,6-diF-phenyl	2-methyl-1-imidazolyl
959	$CONH_2$	2,6-diF-phenyl	5-methyl-1-imidazolyl
960	$CONH_2$	2,6-diF-phenyl	2-methylsulfonyl-1-imidazolyl

Utility

The compounds of this invention are useful as anticoagulants for the treatment or prevention of thromboembolic disorders in mammals. The term "thromboembolic disorders" as used herein includes arterial or venous cardiovascular or cerebrovascular thromboembolic disorders, including, for example, unstable angina, first or recurrent myocardial infarction, ischemic sudden death, transient ischemic attack, stroke, atherosclerosis, venous thrombosis, deep vein thrombosis, thrombophlebitis, arterial embolism, coronary and cerebral arterial thrombosis, cerebral embolism, kidney embolisms, and pulmonary embolisms. The anticoagulant effect of compounds of the present invention is believed to be due to inhibition of factor Xa or thrombin.

The effectiveness of compounds of the present invention as inhibitors of factor Xa was determined using purified human factor Xa and synthetic substrate. The rate of factor Xa hydrolysis of chromogenic substrate S2222 (Kabi Pharmacia, Franklin, OH) was measured both in the absence and presence of compounds of the present invention. Hydrolysis of the substrate resulted in the release of pNA, which was monitored spectrophotometrically by measuring the increase in absorbance at 405 nM. A decrease in the rate of absorbance change at 405 nm in the presence of inhibitor is indicative of enzyme inhibition. The results of this assay are expressed as inhibitory constant, K_i.

Factor Xa determinations were made in 0.10 M sodium phosphate buffer, pH 7.5, containing 0.20 M NaCl, and 0.5 % PEG 8000. The Michaelis constant, K_m, for substrate hydrolysis was determined at 25°C using the method of Lineweaver and Burk. Values of K_i were determined by allowing 0.2-0.5 nM human factor Xa (Enzyme Research Laboratories, South Bend, IN) to react with the substrate (0.20 mM-1 mM) in the presence of inhibitor. Reactions were allowed to go for 30 minutes and the velocities (rate of absorbance change vs time) were measured in the time frame of 25-30 minutes. The following relationship was used to calculate K_i values:

$$(v_o - v_s)/v_s = I/(K_i\ (1 + S/K_m))$$

where:

v_o is the velocity of the control in the absence of inhibitor;

v_s is the velocity in the presence of inhibitor;

I is the concentration of inhibitor;

K_i is the dissociation constant of the enzyme:inhibitor complex;

S is the concentration of substrate;

K_m is the Michaelis constant.

Using the methodology described above, a number of compounds of the present invention were found to exhibit a K_i of $\leq$10 μM, thereby confirming the utility of the compounds of the present invention as effective Xa inhibitors.

The antithrombotic effect of compounds of the present invention can be demonstrated in a rabbit arterio-venous (AV) shunt thrombosis model. In this model, rabbits weighing 2-3 kg anesthetized with a mixture of xylazine (10 mg/kg i.m.) and ketamine (50 mg/kg i.m.) are used. A saline-filled AV shunt device is connected between the femoral arterial and the femoral venous cannulae. The AV shunt device consists of a piece of 6-cm tygon tubing which contains a piece of silk thread. Blood will flow from the femoral artery via the AV-shunt into the femoral vein. The exposure of flowing blood to a silk thread will induce the formation of a significant thrombus. After forty minutes, the shunt is disconnected and the silk thread covered with thrombus is weighed. Test agents or vehicle will be given (i.v., i.p., s.c., or orally) prior to the opening of the AV shunt. The percentage inhibition of thrombus formation is determined for each treatment group. The ID50 values (dose which produces 50% inhibition of thrombus formation) are estimated by linear regression.

The compounds of formula (I) may also be useful as inhibitors of serine proteases, notably human thrombin, plasma kallikrein and plasmin. Because of their inhibitory action, these compounds are indicated for use in the prevention or treatment of physiological reactions, blood coagulation and inflammation, catalyzed by the aforesaid class of enzymes. Specifically, the compounds have utility as drugs for the

treatment of diseases arising from elevated thrombin activity such as myocardial infarction, and as reagents used as anticoagulants in the processing of blood to plasma for diagnostic and other commercial purposes.

Some compounds of the present invention were shown to be direct acting inhibitors of the serine protease thrombin by their ability to inhibit the cleavage of small molecule substrates by thrombin in a purified system. *In vitro* inhibition constants were determined by the method described by Kettner et al. in *J. Biol. Chem.* **265**, 18289-18297 (1990), herein incorporated by reference. In these assays, thrombin-mediated hydrolysis of the chromogenic substrate S2238 (Helena Laboratories, Beaumont, TX) was monitored spectrophotometrically. Addition of an inhibitor to the assay mixture results in decreased absorbance and is indicative of thrombin inhibition. Human thrombin (Enzyme Research Laboratories, Inc., South Bend, IN) at a concentration of 0.2 nM in 0.10 M sodium phosphate buffer, pH 7.5, 0.20 M NaCl, and 0.5% PEG 6000, was incubated with various substrate concentrations ranging from 0.20 to 0.02 mM. After 25 to 30 minutes of incubation, thrombin activity was assayed by monitoring the rate of increase in absorbance at 405 nm which arises owing to substrate hydrolysis. Inhibition constants were derived from reciprocal plots of the reaction velocity as a function of substrate concentration using the standard method of Lineweaver and Burk. Using the methodology described above, some compounds of this invention were evaluated and found to exhibit a K_i of less than 10 μm, thereby confirming the utility of the compounds of the present invention as effective Xa inhibitors.

The compounds of the present invention can be administered alone or in combination with one or more additional therapeutic agents. These include other anti-coagulant or coagulation inhibitory agents, anti-platelet or platelet inhibitory agents, thrombin inhibitors, or thrombolytic or fibrinolytic agents.

The compounds are administered to a mammal in a therapeutically effective amount. By "therapeutically

effective amount" it is meant an amount of a compound of Formula I that, when administered alone or in combination with an additional therapeutic agent to a mammal, is effective to prevent or ameliorate the thromboembolic disease condition or the progression of the disease.

By "administered in combination" or "combination therapy" it is meant that the compound of Formula I and one or more additional therapeutic agents are administered concurrently to the mammal being treated. When administered in combination each component may be administered at the same time or sequentially in any order at different points in time. Thus, each component may be administered separately but sufficiently closely in time so as to provide the desired therapeutic effect. Other anticoagulant agents (or coagulation inhibitory agents) that may be used in combination with the compounds of this invention include warfarin and heparin, as well as other factor Xa inhibitors such as those described in the publications identified above under Background of the Invention.

The term anti-platelet agents (or platelet inhibitory agents), as used herein, denotes agents that inhibit platelet function such as by inhibiting the aggregation, adhesion or granular secretion of platelets. Such agents include, but are not limited to, the various known non-steroidal anti-inflammatory drugs (NSAIDS) such as aspirin, ibuprofen, naproxen, sulindac, indomethacin, mefenamate, droxicam, diclofenac, sulfinpyrazone, and piroxicam, including pharmaceutically acceptable salts or prodrugs thereof. Of the NSAIDS, aspirin (acetylsalicyclic acid or ASA), and piroxicam are preferred. Other suitable anti-platelet agents include ticlopidine, including pharmaceutically acceptable salts or prodrugs thereof. Ticlopidine is also a preferred compound since it is known to be gentle on the gastro-intestinal tract in use. Still other suitable platelet inhibitory agents include IIb/IIIa antagonists, thromboxane-A2-receptor antagonists and thromboxane-A2-synthetase inhibitors, as well as pharmaceutically acceptable salts or prodrugs thereof.

The term thrombin inhibitors (or anti-thrombin agents), as used herein, denotes inhibitors of the serine protease thrombin. By inhibiting thrombin, various thrombin-mediated processes, such as thrombin-mediated platelet activation (that is, for example, the aggregation of platelets, and/or the granular secretion of plasminogen activator inhibitor-1 and/or serotonin) and/or fibrin formation are disrupted. A number of thrombin inhibitors are known to one of skill in the art and these inhibitors are contemplated to be used in combination with the present compounds. Such inhibitors include, but are not limited to, boroarginine derivatives, boropeptides, heparins, hirudin and argatroban, including pharmaceutically acceptable salts and prodrugs thereof. Boroarginine derivatives and boropeptides include N-acetyl and peptide derivatives of boronic acid, such as C-terminal a-aminoboronic acid derivatives of lysine, ornithine, arginine, homoarginine and corresponding isothiouronium analogs thereof. The term hirudin, as used herein, includes suitable derivatives or analogs of hirudin, referred to herein as hirulogs, such as disulfatohirudin. Boropeptide thrombin inhibitors include compounds described in Kettner et al., U.S. Patent No. 5,187,157 and European Patent Application Publication Number 293 881 A2, the disclosures of which are hereby incorporated herein by reference. Other suitable boroarginine derivatives and boropeptide thrombin inhibitors include those disclosed in PCT Application Publication Number 92/07869 and European Patent Application Publication Number 471,651 A2, the disclosures of which are hereby incorporated herein by reference.

The term thrombolytics (or fibrinolytic) agents (or thrombolytics or fibrinolytics), as used herein, denotes agents that lyse blood clots (thrombi). Such agents include tissue plasminogen activator, anistreplase, urokinase or streptokinase, including pharmaceutically acceptable salts or prodrugs thereof. The term anistreplase, as used herein, refers to anisoylated plasminogen streptokinase activator complex, as described, for example, in European Patent Application No. 028,489, the disclosure of which is hereby

incorporated herein by reference herein. The term urokinase, as used herein, is intended to denote both dual and single chain urokinase, the latter also being referred to herein as prourokinase.

Administration of the compounds of Formula I of the invention in combination with such additional therapeutic agent, may afford an efficacy advantage over the compounds and agents alone, and may do so while permitting the use of lower doses of each. A lower dosage minimizes the potential of side effects, thereby providing an increased margin of safety.

The compounds of the present invention are also useful as standard or reference compounds, for example as a quality standard or control, in tests or assays involving the inhibition of factor Xa. Such compounds may be provided in a commercial kit, for example, for use in pharmaceutical research involving factor Xa. For example, a compound of the present invention could be used as a reference in an assay to compare its known activity to a compound with an unknown activity. This would ensure the experimenter that the assay was being performed properly and provide a basis for comparison, especially if the test compound was a derivative of the reference compound. When developing new assays or protocols, compounds according to the present invention could be used to test their effectiveness.

The compounds of the present invention may also be used in diagnostic assays involving factor Xa. For example, the presence of factor Xa in an unknown sample could be determined by addition of chromogenic substrate S2222 to a series of solutions containing test sample and optionally one of the compounds of the present invention. If production of pNA is observed in the solutions containing test sample, but no compound of the present invention, then one would conclude factor Xa was present.

Dosage and Formulation

The compounds of this invention can be administered in such oral dosage forms as tablets, capsules (each of which includes sustained release or timed release formulations),

pills, powders, granules, elixirs, tinctures, suspensions, syrups, and emulsions. They may also be administered in intravenous (bolus or infusion), intraperitoneal, subcutaneous, or intramuscular form, all using dosage forms well known to those of ordinary skill in the pharmaceutical arts. They can be administered alone, but generally will be administered with a pharmaceutical carrier selected on the basis of the chosen route of administration and standard pharmaceutical practice.

The dosage regimen for the compounds of the present invention will, of course, vary depending upon known factors, such as the pharmacodynamic characteristics of the particular agent and its mode and route of administration; the species, age, sex, health, medical condition, and weight of the recipient; the nature and extent of the symptoms; the kind of concurrent treatment; the frequency of treatment; the route of administration, the renal and hepatic function of the patient, and the effect desired. A physician or veterinarian can determine and prescribe the effective amount of the drug required to prevent, counter, or arrest the progress of the thromboembolic disorder.

By way of general guidance, the daily oral dosage of each active ingredient, when used for the indicated effects, will range between about 0.001 to 1000 mg/kg of body weight, preferably between about 0.01 to 100 mg/kg of body weight per day, and most preferably between about 1.0 to 20 mg/kg/day. Intravenously, the most preferred doses will range from about 1 to about 10 mg/kg/minute during a constant rate infusion. Compounds of this invention may be administered in a single daily dose, or the total daily dosage may be administered in divided doses of two, three, or four times daily.

Compounds of this invention can be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal routes, using transdermal skin patches. When administered in the form of a transdermal delivery system, the dosage administration will, of course, be continuous rather than intermittent throughout the dosage regimen.

The compounds are typically administered in admixture with suitable pharmaceutical diluents, excipients, or carriers (collectively referred to herein as pharmaceutical carriers) suitably selected with respect to the intended form of administration, that is, oral tablets, capsules, elixirs, syrups and the like, and consistent with conventional pharmaceutical practices.

For instance, for oral administration in the form of a tablet or capsule, the active drug component can be combined with an oral, non-toxic, pharmaceutically acceptable, inert carrier such as lactose, starch, sucrose, glucose, methyl callulose, magnesium stearate, dicalcium phosphate, calcium sulfate, mannitol, sorbitol and the like; for oral administration in liquid form, the oral drug components can be combined with any oral, non-toxic, pharmaceutically acceptable inert carrier such as ethanol, glycerol, water, and the like. Moreover, when desired or necessary, suitable binders, lubricants, disintegrating agents, and coloring agents can also be incorporated into the mixture. Suitable binders include starch, gelatin, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth, or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes, and the like. Lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride, and the like. Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum, and the like.

The compounds of the present invention can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles, and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine, or phosphatidylcholines.

Compounds of the present invention may also be coupled with soluble polymers as targetable drug carriers. Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxypropylmethacrylamide-phenol,

polyhydroxyethylaspartamidephenol, or polyethyleneoxide-polylysine substituted with palmitoyl residues. Furthermore, the compounds of the present invention may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polyglycolic acid, copolymers of polylactic and polyglycolic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacylates, and crosslinked or amphipathic block copolymers of hydrogels.

Dosage forms (pharmaceutical compositions) suitable for administration may contain from about 1 milligram to about 100 milligrams of active ingredient per dosage unit. In these pharmaceutical compositions the active ingredient will ordinarily be present in an amount of about 0.5-95% by weight based on the total weight of the composition.

Gelatin capsules may contain the active ingredient and powdered carriers, such as lactose, starch, cellulose derivatives, magnesium stearate, stearic acid, and the like. Similar diluents can be used to make compressed tablets. Both tablets and capsules can be manufactured as sustained release products to provide for continuous release of medication over a period of hours. Compressed tablets can be sugar coated or film coated to mask any unpleasant taste and protect the tablet from the atmosphere, or enteric coated for selective disintegration in the gastrointestinal tract.

Liquid dosage forms for oral administration can contain coloring and flavoring to increase patient acceptance.

In general, water, a suitable oil, saline, aqueous dextrose (glucose), and related sugar solutions and glycols such as propylene glycol or polyethylene glycols are suitable carriers for parenteral solutions. Solutions for parenteral administration preferably contain a water soluble salt of the active ingredient, suitable stabilizing agents, and if necessary, buffer substances. Antioxidizing agents such as sodium bisulfite, sodium sulfite, or ascorbic acid, either alone or combined, are suitable stabilizing agents. Also used are citric acid and its salts and sodium EDTA. In addition,

parenteral solutions can contain preservatives, such as benzalkonium chloride, methyl- or propyl-paraben, and chlorobutanol.

Suitable pharmaceutical carriers are described in Remington's Pharmaceutical Sciences, Mack Publishing Company, a standard reference text in this field.

Representative useful pharmaceutical dosage-forms for administration of the compounds of this invention can be illustrated as follows:

Capsules

A large number of unit capsules can be prepared by filling standard two-piece hard gelatin capsules each with 100 milligrams of powdered active ingredient, 150 milligrams of lactose, 50 milligrams of cellulose, and 6 milligrams magnesium stearate.

Soft Gelatin Capsules

A mixture of active ingredient in a digestable oil such as soybean oil, cottonseed oil or olive oil may be prepared and injected by means of a positive displacement pump into gelatin to form soft gelatin capsules containing 100 milligrams of the active ingredient. The capsules should be washed and dried.

Tablets

Tablets may be prepared by conventional procedures so that the dosage unit is 100 milligrams of active ingredient, 0.2 milligrams of colloidal silicon dioxide, 5 milligrams of magnesium stearate, 275 milligrams of microcrystalline cellulose, 11 milligrams of starch and 98.8 milligrams of lactose. Appropriate coatings may be applied to increase palatability or delay absorption.

Injectable

A parenteral composition suitable for administration by injection may be prepared by stirring 1.5% by weight of active ingredient in 10% by volume propylene glycol and water. The solution should be made isotonic with sodium chloride and sterilized.

Suspension

An aqueous suspension can be prepared for oral administration so that each 5 mL contain 100 mg of finely divided active ingredient, 200 mg of sodium carboxymethyl cellulose, 5 mg of sodium benzoate, 1.0 g of sorbitol solution, U.S.P., and 0.025 mL of vanillin.

Where the compounds of this invention are combined with other anticoagulant agents, for example, a daily dosage may be about 0.1 to 100 milligrams of the compound of Formula I and about 1 to 7.5 milligrams of the second anticoagulant, per kilogram of patient body weight. For a tablet dosage form, the compounds of this invention generally may be present in an amount of about 5 to 10 milligrams per dosage unit, and the second anti-coagulant in an amount of about 1 to 5 milligrams per dosage unit.

Where the compounds of Formula I are administered in combination with an anti-platelet agent, by way of general guidance, typically a daily dosage may be about 0.01 to 25 milligrams of the compound of Formula I and about 50 to 150 milligrams of the anti-platelet agent, preferably about 0.1 to 1 milligrams of the compound of Formula I and about 1 to 3 milligrams of antiplatelet agents, per kilogram of patient body weight.

Where the compounds of Formula I are adminstered in combination with thrombolytic agent, typically a daily dosage may be about 0.1 to 1 milligrams of the compound of Formula I, per kilogram of patient body weight and, in the case of the thrombolytic agents, the usual dosage of the thrombolyic agent when administered alone may be reduced by about 70-80% when administered with a compound of Formula I.

Where two or more of the foregoing second therapeutic agents are administered with the compound of Formula I, generally the amount of each component in a typical daily dosage and typical dosage form may be reduced relative to the usual dosage of the agent when administered alone, in view of the additive or synergistic effect of the therapeutic agents when administered in combination.

Particularly when provided as a single dosage unit, the potential exists for a chemical interaction between the combined active ingredients. For this reason, when the compound of Formula I and a second therapeutic agent are combined in a single dosage unit they are formulated such that although the active ingredients are combined in a single dosage unit, the physical contact between the active ingredients is minimized (that is, reduced). For example, one active ingredient may be enteric coated. By enteric coating one of the active ingredients, it is possible not only to minimize the contact between the combined active ingredients, but also, it is possible to control the release of one of these components in the gastrointestinal tract such that one of these components is not released in the stomach but rather is released in the intestines. One of the active ingredients may also be coated with a material which effects a sustained-release throughout the gastrointestinal tract and also serves to minimize physical contact between the combined active ingredients. Furthermore, the sustained-released component can be additionally enteric coated such that the release of this component occurs only in the intestine. Still another approach would involve the formulation of a combination product in which the one component is coated with a sustained and/or enteric release polymer, and the other component is also coated with a polymer such as a lowviscosity grade of hydroxypropyl methylcellulose (HPMC) or other appropriate materials as known in the art, in order to further separate the active components. The polymer coating serves to form an additional barrier to interaction with the other component.

These as well as other ways of minimizing contact between the components of combination products of the present invention, whether administered in a single dosage form or administered in separate forms but at the same time by the same manner, will be readily apparent to those skilled in the art, once armed with the present disclosure.

Obviously, numerous modifications and variations of the present invention are possible in light of the above teachings. It is therefore to be understood that within the

scope of the appended claims, the invention may be practiced otherwise that as specifically described herein.

WHAT IS CLAIMED AS NEW AND DESIRED TO BE SECURED BY LETTER PATENT OF UNITED STATES IS:

1. A compound of formula I:



I

or a stereoisomer or pharmaceutically acceptable salt thereof, wherein;

ring M contains, in addition to J, 0-2 N atoms;

J is O or S;

D is selected from CN, $C(=NR^8)NR^7R^9$, $NHC(=NR^8)NR^7R^9$, $NR^8CH(=NR^7)$, $C(O)NR^7R^8$, and $(CR^8R^9)_tNR^7R^8$, provided that D is substituted meta or para to G on E;

E is selected from phenyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, and piperidinyl substituted with 1 R;

alternatively, D-E-G together represent pyridyl substituted with 1 R;

R is selected from H, halogen, $(CH_2)_tOR^3$, C_{1-4} alkyl, OCF_3, and CF_3;

G is absent or is selected from $NHCH_2$, OCH_2, and SCH_2;

Z is selected from a C_{1-4} alkylene, $(CH_2)_rO(CH_2)_r$, $(CH_2)_rNR^3(CH_2)_r$, $(CH_2)_rC(O)(CH_2)_r$, $(CH_2)_rC(O)O(CH_2)_r$, $(CH_2)_rOC(O)(CH_2)_r$, $(CH_2)_rC(O)NR^3(CH_2)_r$, $(CH_2)_rNR^3C(O)(CH_2)_r$, $(CH_2)_rOC(O)O(CH_2)_r$, $(CH_2)_rOC(O)NR^3(CH_2)_r$, $(CH_2)_rNR^3C(O)O(CH_2)_r$, $(CH_2)_rNR^3C(O)NR^3(CH_2)_r$, $(CH_2)_rS(O)_p(CH_2)_r$, $(CH_2)_rSO_2NR^3(CH_2)_r$, $(CH_2)_rNR^3SO_2(CH_2)_r$, and

$(CH_2)_rNR^3SO_2NR^3(CH_2)_r$, provided that Z does not form a N-N, N-O, N-S, NCH_2N, NCH_2O, or NCH_2S bond with ring M or group A;

R^{1a} and R^{1b} are independently absent or selected from $-(CH_2)_r-R^{1'}$, $NCH_2R^{1''}$, $OCH_2R^{1''}$, $SCH_2R^{1''}$, $N(CH_2)_2(CH_2)_tR^{1'}$, $O(CH_2)_2(CH_2)_tR^{1'}$, and $S(CH_2)_2(CH_2)_tR^{1'}$, or combined to form a 5-8 membered saturated, partially saturated or unsaturated ring substituted with 0-2 R^4 and which contains from 0-2 heteroatoms selected from the group consisting of N, O, and S;

$R^{1'}$ is selected from H, C_{1-3} alkyl, halo, $(CF_2)_rCF_3$, OR^2, NR^2R^{2a}, $C(O)R^{2c}$, $OC(O)R^2$, $(CF_2)_rCO_2R^{2c}$, $S(O)_pR^{2b}$, $NR^2(CH_2)_rOR^2$, $NR^2C(O)R^{2b}$, $NR^2C(O)NHR^{2b}$, $NR^2C(O)_2R^{2a}$, $OC(O)NR^{2b}$, $C(O)NR^2R^{2a}$, $SO_2NR^2R^{2a}$, $NR^2SO_2R^{2b}$, C_{3-6} carbocyclic residue substituted with 0-2 R^4, and 5-10 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R^4;

$R^{1''}$ is selected from H, $C(O)R^{2b}$, $C(O)NR^2R^{2a}$, $S(O)R^{2b}$, $S(O)_2R^{2b}$, and $SO_2NR^2R^{2a}$;

R^2, at each occurrence, is selected from H, CF_3, C_{1-6} alkyl, benzyl, C_{3-6} carbocyclic residue substituted with 0-2 R^{4b}, and 5-6 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R^{4b};

R^{2a}, at each occurrence, is selected from H, CF_3, C_{1-6} alkyl, benzyl, C_{3-6} carbocyclic residue substituted with 0-2 R^{4b}, and 5-6 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R^{4b};

R^{2b}, at each occurrence, is selected from CF_3, C_{1-4} alkoxy, C_{1-6} alkyl, benzyl, C_{3-6} carbocyclic residue substituted with

0-2 R^{4b}, and 5-6 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R^{4b};

R^{2c}, at each occurrence, is selected from CF_3, OH, C_{1-4} alkoxy, C_{1-6} alkyl, benzyl, C_{3-6} carbocyclic residue substituted with 0-2 R^{4b}, and 5-6 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R^{4b};

alternatively, R^2 and R^{2a} combine to form a 5 or 6 membered saturated, partially saturated or unsaturated ring substituted with 0-2 R^{4b} which contains from 0-1 additional heteroatoms selected from the group consisting of N, O, and S;

R^3, at each occurrence, is selected from H, C_{1-4} alkyl, and phenyl;

R^{3a}, at each occurrence, is selected from H, C_{1-4} alkyl, and phenyl;

A is selected from:

C_{3-10} carbocyclic residue substituted with 0-2 R^4, and

5-10 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R^4;

B is selected from:

X-Y, NR^2R^{2a}, $C(=NR^2)NR^2R^{2a}$, $NR^2C(=NR^2)NR^2R^{2a}$,

C_{3-10} carbocyclic residue substituted with 0-2 R^{4a}, and

5-10 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R^{4a};

X is selected from C_{1-4} alkylene, $-CR^2(CR^2R^{2b})(CH_2)_t-$, $-C(O)-$, $-C(=NR)-$, $-CR^2(NR^1"R^2)-$, $-CR^2(OR^2)-$, $-CR^2(SR^2)-$, $-C(O)CR^2R^{2a}-$, $-CR^2R^{2a}C(O)$, $-S(O)_p-$, $-S(O)_pCR^2R^{2a}-$,

$-CR^2R^{2a}S(O)_p-$, $-S(O)_2NR^2-$, $-NR^2S(O)_2-$, $-NR^2S(O)_2CR^2R^{2a}-$, $-CR^2R^{2a}S(O)_2NR^2-$, $-NR^2S(O)_2NR^2-$, $-C(O)NR^2-$, $-NR^2C(O)-$, $-C(O)NR^2CR^2R^{2a}-$, $-NR^2C(O)CR^2R^{2a}-$, $-CR^2R^{2a}C(O)NR^2-$, $-CR^2R^{2a}NR^2C(O)-$, $-NR^2C(O)O-$, $-OC(O)NR^2-$, $-NR^2C(O)NR^2-$, $-NR^2-$, $-NR^2CR^2R^{2a}-$, $-CR^2R^{2a}NR^2-$, O, $-CR^2R^{2a}O-$, and $-OCR^2R^{2a}-$;

Y is selected from:

$(CH_2)_rNR^2R^{2a}$, provided that X-Y do not form a N-N, O-N, or S-N bond,

C_{3-10} carbocyclic residue substituted with 0-2 R^{4a}, and

5-10 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R^{4a};

R^4, at each occurrence, is selected from =O, $(CH_2)_rOR^2$, halo, C_{1-4} alkyl, -CN, NO_2, $(CH_2)_rNR^2R^{2a}$, $(CH_2)_rC(O)R^{2b}$, $NR^2C(O)R^{2b}$, $C(O)NR^2R^{2a}$, $NR^2C(O)NR^2R^{2a}$, $CH(=NR^2)NR^2R^{2a}$, $NHC(=NR^2)NR^2R^{2a}$, $SO_2NR^2R^{2a}$, $NR^2SO_2NR^2R^{2a}$, $NR^2SO_2-C_{1-4}$ alkyl, $NR^2SO_2R^5$, $S(O)_pR^5$, $(CF_2)_rCF_3$, $NCH_2R^{1'}$, $OCH_2R^{1'}$, $SCH_2R^{1'}$, $N(CH_2)_2(CH_2)_tR^{1'}$, $O(CH_2)_2(CH_2)_tR^{1'}$, and $S(CH_2)_2(CH_2)_tR^{1'}$,

alternatively, one R^4 is a 5-6 membered aromatic heterocycle containing from 1-4 heteroatoms selected from the group consisting of N, O, and S;

R^{4a}, at each occurrence, is selected from =O, $(CH_2)_rOR^2$, halo, C_{1-4} alkyl, -CN, NO_2, $(CH_2)_rNR^2R^{2a}$, $(CH_2)_rC(O)R^{2b}$, $NR^2C(O)R^{2b}$, $C(O)NR^2R^{2a}$, $NR^2C(O)NR^2R^{2a}$, $CH(=NR^2)NR^2R^{2a}$, $NHC(=NR^2)NR^2R^{2a}$, $SO_2NR^2R^{2a}$, $NR^2SO_2NR^2R^{2a}$, $NR^2SO_2-C_{1-4}$ alkyl, $NR^2SO_2R^5$, $S(O)_pR^5$, and $(CF_2)_rCF_3$;

alternatively, one R^{4a} is a 5-6 membered aromatic heterocycle containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-1 R^5;

R^{4b}, at each occurrence, is selected from =O, $(CH_2)_rOR^3$, halo, C_{1-4} alkyl, -CN, NO_2, $(CH_2)_rNR^3R^{3a}$, $(CH_2)_rC(O)R^3$,

$NR^3C(O)R^{3a}$, $C(O)NR^3R^{3a}$, $NR^3C(O)NR^3R^{3a}$, $CH(=NR^3)NR^3R^{3a}$, $NH^3C(=NR^3)NR^3R^{3a}$, $SO_2NR^3R^{3a}$, $NR^3SO_2NR^3R^{3a}$, NR^3SO_2-C_{1-4} alkyl, $NR^3SO_2CF_3$, NR^3SO_2-phenyl, $S(O)_pCF_3$, $S(O)_p$-C_{1-4} alkyl, $S(O)_p$-phenyl, and $(CF_2)_rCF_3$;

R^5, at each occurrence, is selected from CF_3, C_{1-6} alkyl, phenyl substituted with 0-2 R^6, and benzyl substituted with 0-2 R^6;

R^6, at each occurrence, is selected from H, OH, $(CH_2)_rOR^2$, halo, C_{1-4} alkyl, CN, NO_2, $(CH_2)_rNR^2R^{2a}$, $(CH_2)_rC(O)R^{2b}$, $NR^2C(O)R^{2b}$, $NR^2C(O)NR^2R^{2a}$, $CH(=NH)NH_2$, $NHC(=NH)NH_2$, $SO_2NR^2R^{2a}$, $NR^2SO_2NR^2R^{2a}$, and $NR^2SO_2C_{1-4}$ alkyl;

R^7, at each occurrence, is selected from H, OH, C_{1-6} alkyl, C_{1-6} alkylcarbonyl, C_{1-6} alkoxy, C_{1-4} alkoxycarbonyl, $(CH_2)_n$-phenyl, C_{6-10} aryloxy, C_{6-10} aryloxycarbonyl, C_{6-10} arylmethylcarbonyl, C_{1-4} alkylcarbonyloxy C_{1-4} alkoxycarbonyl, C_{6-10} arylcarbonyloxy C_{1-4} alkoxycarbonyl, C_{1-6} alkylaminocarbonyl, phenylaminocarbonyl, and phenyl C_{1-4} alkoxycarbonyl;

R^8, at each occurrence, is selected from H, C_{1-6} alkyl and $(CH_2)_n$-phenyl;

alternatively, R^7 and R^8 combine to form a 5 or 6 membered saturated, ring which contains from 0-1 additional heteroatoms selected from the group consisting of N, O, and S;

R^9, at each occurrence, is selected from H, C_{1-6} alkyl and $(CH_2)_n$-phenyl;

n, at each occurrence, is selected from 0, 1, 2, and 3;

m, at each occurrence, is selected from 0, 1, and 2;

p, at each occurrence, is selected from 0, 1, and 2;

r, at each occurrence, is selected from 0, 1, 2, and 3;

s, at each occurrence, is selected from 0, 1, and 2; and,

t, at each occurrence, is selected from 0 and 1;

provided that D-E-G-$(CH_2)_s$- and -Z-A-B are not both benzamidines.

2. A compound according to Claim 1, wherein the compound is of formulae Ia-If:



Ia



Ib



Ic



Id



Ie



If

wherein, groups D-E- and -Z-A-B are attached to adjacent atoms on the ring;

Z is selected from a CH_2O, OCH_2, CH_2NH, $NHCH_2$, C(O), $CH_2C(O)$, $C(O)CH_2$, NHC(O), C(O)NH, $CH_2S(O)_2$, $S(O)_2(CH_2)$, SO_2NH, and $NHSO_2$, provided that Z does not form a N-N, N-O, NCH_2N, or NCH_2O bond with ring M or group A;

A is selected from one of the following carbocyclic and heterocyclic systems which are substituted with 0-2 R^4;

phenyl, piperidinyl, piperazinyl, pyridyl, pyrimidyl, furanyl, morpholinyl, thiophenyl, pyrrolyl, pyrrolidinyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, triazolyl, 1,2,3-oxadiazolyl,

1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl, benzofuranyl, benzothiofuranyl, indolyl, benzimidazolyl, benzoxazolyl, benzthiazolyl, indazolyl, benzisoxazolyl, benzisothiazolyl, and isoindazolyl;

B is selected from: Y, X-Y, NR^2R^{2a}, $C(=NR^2)NR^2R^{2a}$, and $NR^2C(=NR^2)NR^2R^{2a}$;

X is selected from C_{1-4} alkylene, -C(O)-, -C(=NR)-, $-CR^2(NR^2R^{2a})-$, $-C(O)CR^2R^{2a}-$, $-CR^2R^{2a}C(O)$, $-C(O)NR^2-$, $-NR^2C(O)-$, $-C(O)NR^2CR^2R^{2a}-$, $-NR^2C(O)CR^2R^{2a}-$, $-CR^2R^{2a}C(O)NR^2-$, $-CR^2R^{2a}NR^2C(O)-$, $-NR^2C(O)NR^2-$, $-NR^2-$, $-NR^2CR^2R^{2a}-$, $-CR^2R^{2a}NR^2-$, O, $-CR^2R^{2a}O-$, and $-OCR^2R^{2a}-$;

Y is NR^2R^{2a}, provided that X-Y do not form a N-N or O-N bond;

alternatively, Y is selected from one of the following carbocyclic and heterocyclic systems which are substituted with 0-2 R^{4a};

cylcopropyl, cyclopentyl, cyclohexyl, phenyl, piperidinyl, piperazinyl, pyridyl, pyrimidyl, furanyl, morpholinyl, thiophenyl, pyrrolyl, pyrrolidinyl, oxazolyl, isoxazolyl, isoxazolinyl, thiazolyl, isothiazolyl, pyrazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, triazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl, benzofuranyl, benzothiofuranyl, indolyl, benzimidazolyl, benzoxazolyl, benzthiazolyl, indazolyl, benzisoxazolyl, benzisothiazolyl, and isoindazolyl;

alternatively, Y is selected from the following bicyclic heteroaryl ring systems:



K is selected from O, S, NH, and N.

3. A compound according to Claim 2, wherein the compound is of formulae Ib and Ic:



wherein;

J is O or S; and,

Z is selected from a C(O), $CH_2C(O)$, $C(O)CH_2$, NHC(O), C(O)NH, $C(O)N(CH_3)$, $CH_2S(O)_2$, $S(O)_2(CH_2)$, SO_2NH, and $NHSO_2$, provided that Z does not form a N-N or NCH_2N bond with ring M or group A.

4. A compound according to Claim 3, wherein the compound is of formulae Ib and Ic:

E is phenyl substituted with R or 2-pyridyl substituted with R;

D is selected from NH_2, $C(O)NH_2$, $C(=NH)NH_2$, CH_2NH_2, CH_2NHCH_3, $CH(CH_3)NH_2$, and $C(CH_3)_2NH_2$, provided that D is substituted meta or para to ring M on E; and,

R is selected from H, OCH_3, Cl, and F.

5. A compound according to Claim 4, wherein the compound is of formulae Ib and Ic:

D-E is selected from 3-aminophenyl, 3-amidinophenyl, 3-aminomethylphenyl, 3-aminocarbonylphenyl, 3-(methylaminomethyl)phenyl, 3-(1-aminoethyl)phenyl, 3-(2-amino-2-propyl)phenyl, 4-chloro-3-aminophenyl, 4-chloro-3-amidinophenyl, 4-chloro-3-aminomethylphenyl, 4-chloro-3-(methylaminomethyl)phenyl, 4-fluoro-3-aminophenyl, 4-fluoro-3-amidinophenyl, 4-fluoro-3-aminomethylphenyl, 4-fluoro-3-(methylaminomethyl)phenyl, 6-aminopyrid-2-yl, 6-amidinopyrid-2-yl, 6-aminomethylpyrid-2-yl, 6-aminocarbonylpyrid-2-yl, 6-(methylaminomethyl)pyrid-2-yl, 6-(1-aminoethyl)pyrid-2-yl, and 6-(2-amino-2-propyl)pyrid-2-yl.

6. A compound according to Claim 3, wherein the compound is of formulae Ib and Ic:

Z is $C(O)CH_2$ and CONH, provided that Z does not form a N-N bond with group A;

A is selected from phenyl, pyridyl, and pyrimidyl, and is substituted with 0-2 R^4; and,

B is selected from X-Y, phenyl, pyrrolidino, morpholino, 1,2,3-triazolyl, and imidazolyl, and is substituted with 0-1 R^{4a};

R^4, at each occurrence, is selected from OH, $(CH_2)_rOR^2$, halo, C_{1-4} alkyl, $(CH_2)_rNR^2R^{2a}$, and $(CF_2)_rCF_3$;

R^{4a} is selected from C_{1-4} alkyl, CF_3, $S(O)_pR^5$, $SO_2NR^2R^{2a}$, and 1-CF_3-tetrazol-2-yl;

R^5, at each occurrence, is selected from CF_3, C_{1-6} alkyl, phenyl, and benzyl;

X is CH_2 or C(O); and,

Y is selected from pyrrolidino and morpholino.

7. A compound according to Claim 6, wherein the compound is of formulae Ib and Ic:

A is selected from the group: phenyl, 2-pyridyl, 3-pyridyl, 2-pyrimidyl, 2-Cl-phenyl, 3-Cl-phenyl, 2-F-phenyl, 3-F-phenyl, 2-methylphenyl, 2-aminophenyl, and 2-methoxyphenyl; and,

B is selected from the group: 2-CF_3-phenyl, 2-(aminosulfonyl)phenyl, 2-(methylaminosulfonyl)phenyl, 2-(dimethylaminosulfonyl)phenyl, 1-pyrrolidinocarbonyl, 2-(methylsulfonyl)phenyl, 4-morpholino, 2-(1'-CF_3-tetrazol-2-yl)phenyl, 4-morpholinocarbonyl, 2-methyl-1-imidazolyl, 5-methyl-1-imidazolyl, 2-methylsulfonyl-1-imidazolyl and, 5-methyl-1,2,3-triazolyl.

8. A compound according to Claim 3, wherein the compound is of formulae Ib and Ic:

E is phenyl substituted with R or 2-pyridyl substituted with R;

D is selected from NH_2, $C(O)NH_2$, $C(=NH)NH_2$, CH_2NH_2, CH_2NHCH_3, $CH(CH_3)NH_2$, and $C(CH_3)_2NH_2$, provided that D is substituted meta or para to ring M on E; and,

R is selected from H, OCH_3, Cl, and F;

Z is $C(O)CH_2$ and CONH, provided that Z does not form a N-N bond with group A;

A is selected from phenyl, pyridyl, and pyrimidyl, and is substituted with 0-2 R^4; and,

B is selected from X-Y, phenyl, pyrrolidino, morpholino, 1,2,3-triazolyl, and imidazolyl, and is substituted with 0-1 R^{4a};

R^4, at each occurrence, is selected from OH, $(CH_2)_rOR^2$, halo, C_{1-4} alkyl, $(CH_2)_rNR^2R^{2a}$, and $(CF_2)_rCF_3$;

R^{4a} is selected from C_{1-4} alkyl, CF_3, $S(O)_pR^5$, $SO_2NR^2R^{2a}$, and 1-CF_3-tetrazol-2-yl;

R^5, at each occurrence, is selected from CF_3, C_{1-6} alkyl, phenyl, and benzyl;

X is CH_2 or C(O); and,

Y is selected from pyrrolidino and morpholino.

9. A compound according to Claim 8, wherein the compound is of formulae Ib and Ic:

D-E is selected from 3-aminophenyl, 3-amidinophenyl, 3-aminomethylphenyl, 3-aminocarbonylphenyl, 3-

(methylaminomethyl)phenyl, 3-(1-aminoethyl)phenyl, 3-(2-amino-2-propyl)phenyl, 4-chloro-3-aminophenyl, 4-chloro-3-amidinophenyl, 4-chloro-3-aminomethylphenyl, 4-chloro-3-(methylaminomethyl)phenyl, 4-fluoro-3-aminophenyl, 4-fluoro-3-amidinophenyl, 4-fluoro-3-aminomethylphenyl, 4-fluoro-3-(methylaminomethyl)phenyl, 6-aminopyrid-2-yl, 6-amidinopyrid-2-yl, 6-aminomethylpyrid-2-yl, 6-aminocarbonylpyrid-2-yl, 6-(methylaminomethyl)pyrid-2-yl, 6-(1-aminoethyl)pyrid-2-yl, 6-(2-amino-2-propyl)pyrid-2-yl;

A is selected from the group: phenyl, 2-pyridyl, 3-pyridyl, 2-pyrimidyl, 2-Cl-phenyl, 3-Cl-phenyl, 2-F-phenyl, 3-F-phenyl, 2-methylphenyl, 2-aminophenyl, and 2-methoxyphenyl; and,

B is selected from the group: 2-CF_3-phenyl, 2-(aminosulfonyl)phenyl, 2-(methylaminosulfonyl)phenyl, 2-(dimethylaminosulfonyl)phenyl, 1-pyrrolidinocarbonyl, 2-(methylsulfonyl)phenyl, 4-morpholino, 2-(1'-CF_3-tetrazol-2-yl)phenyl, 4-morpholinocarbonyl, 2-methyl-1-imidazolyl, 5-methyl-1-imidazolyl, 2-methylsulfonyl-1-imidazolyl and, 5-methyl-1,2,3-triazolyl.

10. A compound according to Claim 9, wherein the compound is of formula Ib_1.

11. A compound according to Claim 9, wherein the compound is of formula Ib_2.

12. A compound according to Claim 9, wherein the compound is of formula Ib_3.

13. A compound according to Claim 9, wherein the compound is of formula Ib_4.

14. A compound according to Claim 9, wherein the compound is of formula Ic_1.

15. A compound according to Claim 9, wherein the compound is of formula Ic_2.

16. A compound according to Claim 3, wherein the compound is of formulae Ib and Ic:

D is selected from $C(=NR^8)NR^7R^9$, $C(O)NR^7R^8$, NR^7R^8, and $CH_2NR^7R^8$, provided that D is substituted meta or para to ring M on E;

E is phenyl substituted with R or pyridyl substituted with R;

R is selected from H, Cl, F, OR^3, CH_3, CH_2CH_3, OCF_3, and CF_3;

Z is selected from C(O), $CH_2C(O)$, $C(O)CH_2$, NHC(O), and C(O)NH, provided that Z does not form a N-N bond with ring M or group A;

R^{1a} and R^{1b} are independently absent or selected from $-(CH_2)_r-R^{1'}$, $NCH_2R^{1''}$, $OCH_2R^{1''}$, $SCH_2R^{1''}$, $N(CH_2)_2(CH_2)_tR^{1'}$, $O(CH_2)_2(CH_2)_tR^{1'}$, and $S(CH_2)_2(CH_2)_tR^{1'}$, or combined to form a 5-8 membered saturated, partially saturated or unsaturated ring substituted with 0-2 R^4 and which contains from 0-2 heteroatoms selected from the group consisting of N, O, and S;

$R^{1'}$, at each occurrence, is selected from H, C_{1-3} alkyl, halo, $(CF_2)_rCF_3$, OR^2, NR^2R^{2a}, $C(O)R^{2c}$, $(CF_2)_rCO_2R^{2c}$, $S(O)_pR^{2b}$,

$NR^2(CH_2)_rOR^2$, $NR^2C(O)R^{2b}$, $NR^2C(O)_2R^{2b}$, $C(O)NR^2R^{2a}$, $SO_2NR^2R^{2a}$, and $NR^2SO_2R^{2b}$;

A is selected from one of the following carbocyclic and heterocyclic systems which are substituted with 0-2 R^4;

phenyl, piperidinyl, piperazinyl, pyridyl, pyrimidyl, furanyl, morpholinyl, thiophenyl, pyrrolyl, pyrrolidinyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, and imidazolyl;

B is selected from: Y, X-Y, NR^2R^{2a}, $C(=NR^2)NR^2R^{2a}$, and $NR^2C(=NR^2)NR^2R^{2a}$;

X is selected from CH_2, $-CR^2(CR^2R^{2b})(CH_2)_t-$, $-C(O)-$, $-C(=NR)-$, $-CH(NR^2R^{2a})-$, $-C(O)NR^2-$, $-NR^2C(O)-$, $-NR^2C(O)NR^2-$, $-NR^2-$, and O;

Y is NR^2R^{2a}, provided that X-Y do not form a N-N or O-N bond;

alternatively, Y is selected from one of the following carbocyclic and heterocyclic systems which are substituted with 0-2 R^{4a};

phenyl, piperidinyl, piperazinyl, pyridyl, pyrimidyl, furanyl, morpholinyl, thiophenyl, pyrrolyl, pyrrolidinyl, oxazolyl, isoxazolyl, isoxazolinyl, thiazolyl, isothiazolyl, pyrazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, triazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, and 1,3,4-triazolyl;

R^4, at each occurrence, is selected from =O, OH, Cl, F, C_{1-4} alkyl, $(CH_2)_rNR^2R^{2a}$, $(CH_2)_rC(O)R^{2b}$, $NR^2C(O)R^{2b}$, $C(O)NR^2R^{2a}$, $CH(=NH)NH_2$, $NHC(=NH)NH_2$, $SO_2NR^2R^{2a}$, NR^2SO_2-C_{1-4} alkyl, $NR^2SO_2R^5$, $S(O)_pR^5$, and $(CF_2)_rCF_3$;

R^{4a}, at each occurrence, is selected from =O, OH, Cl, F, C_{1-4} alkyl, $(CH_2)_rNR^2R^{2a}$, $(CH_2)_rC(O)R^{2b}$, $NR^2C(O)R^{2b}$, $C(O)NR^2R^{2a}$, $CH(=NH)NH_2$, $NHC(=NH)NH_2$, $SO_2NR^2R^{2a}$, $NR^2SO_2-C_{1-4}$ alkyl, $NR^2SO_2R^5$, $S(O)_pR^5$, $(CF_2)_rCF_3$, and 1-CF_3-tetrazol-2-yl;

R^5, at each occurrence, is selected from CF_3, C_{1-6} alkyl, phenyl substituted with 0-2 R^6, and benzyl substituted with 0-2 R^6;

R^6, at each occurrence, is selected from H, =O, OH, OR^2, Cl, F, CH_3, CN, NO_2, $(CH_2)_rNR^2R^{2a}$, $(CH_2)_rC(O)R^{2b}$, $NR^2C(O)R^{2b}$, $CH(=NH)NH_2$, $NHC(=NH)NH_2$, and $SO_2NR^2R^{2a}$;

R^7, at each occurrence, is selected from H, OH, C_{1-6} alkyl, C_{1-6} alkylcarbonyl, C_{1-6} alkoxy, C_{1-4} alkoxycarbonyl, benzyl, C_{6-10} aryloxy, C_{6-10} aryloxycarbonyl, C_{6-10} arylmethylcarbonyl, C_{1-4} alkylcarbonyloxy C_{1-4} alkoxycarbonyl, C_{6-10} arylcarbonyloxy C_{1-4} alkoxycarbonyl, C_{1-6} alkylaminocarbonyl, phenylaminocarbonyl, and phenyl C_{1-4} alkoxycarbonyl;

R^8, at each occurrence, is selected from H, C_{1-6} alkyl and benzyl; and

alternatively, R^7 and R^8 combine to form a morpholino group; and,

R^9, at each occurrence, is selected from H, C_{1-6} alkyl and benzyl.

17. A compound according to Claim 16, wherein the compound is of formulae Ib and Ic:

E is phenyl substituted with R or 2-pyridyl substituted with R;

R is selected from H, Cl, F, OCH_3, CH_3, OCF_3, and CF_3;

Z is selected from a $C(O)CH_2$ and $C(O)NH$, provided that Z does not form a N-N bond with group A;

R^{1a} is selected from H, CH_3, CH_2CH_3, Cl, F, CF_3, OCH_3, $NR^{2}R^{2a}$, $S(O)_pR^{2b}$, $CH_2S(O)_pR^{2b}$, $CH_2NR^{2}S(O)_pR^{2b}$, $C(O)R^{2c}$, $CH_2C(O)R^{2c}$, $C(O)NR^{2}R^{2a}$, and $SO_2NR^{2}R^{2a}$;

R^{1b} is selected from H, CH_3, CH_2CH_3, Cl, F, CF_3, OCH_3, $NR^{2}R^{2a}$, $S(O)_pR^{2b}$, $CH_2S(O)_pR^{2b}$, $CH_2NR^{2}S(O)_pR^{2b}$, $C(O)R^{2c}$, $CH_2C(O)R^{2c}$, $C(O)NR^{2}R^{2a}$, and $SO_2NR^{2}R^{2a}$;

A is selected from one of the following carbocyclic and heterocyclic systems which are substituted with 0-2 R^4;

phenyl, pyridyl, pyrimidyl, furanyl, thiophenyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, and imidazolyl;

B is selected from: Y and X-Y;

X is selected from CH_2, $-CR^{2}(CR^{2}R^{2b})-$, $-C(O)-$, $-C(=NR)-$, $-CH(NR^{2}R^{2a})-$, $-C(O)NR^{2}-$, $-NR^{2}C(O)-$, $-NR^{2}C(O)NR^{2}-$, $-NR^{2}-$, and O;

Y is $NR^{2}R^{2a}$, provided that X-Y do not form a N-N or O-N bond;

alternatively, Y is selected from one of the following carbocyclic and heterocyclic systems which are substituted with 0-2 R^{4a};

phenyl, piperidinyl, piperazinyl, pyridyl, pyrimidyl, furanyl, morpholinyl, thiophenyl, pyrrolyl, pyrrolidinyl, oxazolyl, isoxazolyl, isoxazolinyl, thiazolyl, isothiazolyl, pyrazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, triazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, and 1,3,4-triazolyl;

R^2, at each occurrence, is selected from H, CF_3, CH_3, benzyl, and phenyl;

R^{2a}, at each occurrence, is selected from H, CF_3, CH_3, benzyl, and phenyl;

R^{2b}, at each occurrence, is selected from CF_3, OCH_3, CH_3, benzyl, and phenyl;

R^{2c}, at each occurrence, is selected from CF_3, OH, OCH_3, CH_3, benzyl, and phenyl;

alternatively, R^2 and R^{2a} combine to form a 5 or 6 membered saturated, partially unsaturated, or unsaturated ring which contains from 0-1 additional heteroatoms selected from the group consisting of N, O, and S;

R^3, at each occurrence, is selected from H, CH_3, CH_2CH_3, and phenyl;

R^{3a}, at each occurrence, is selected from H, CH_3, CH_2CH_3, and phenyl;

R^4, at each occurrence, is selected from OH, Cl, F, CH_3, CH_2CH_3, NR^2R^{2a}, $CH_2NR^2R^{2a}$, $C(O)R^{2b}$, $NR^2C(O)R^{2b}$, $C(O)NR^2R^{2a}$, and CF_3;

R^{4a}, at each occurrence, is selected from OH, Cl, F, CH_3, CH_2CH_3, NR^2R^{2a}, $CH_2NR^2R^{2a}$, $C(O)R^{2b}$, $C(O)NR^2R^{2a}$, $SO_2NR^2R^{2a}$, $S(O)_pR^5$, CF_3, and 1-CF_3-tetrazol-2-yl;

R^5, at each occurrence, is selected from CF_3, C_{1-6} alkyl, phenyl substituted with 0-2 R^6, and benzyl substituted with 1 R^6;

R^6, at each occurrence, is selected from H, OH, OCH_3, Cl, F, CH_3, CN, NO_2, NR^2R^{2a}, $CH_2NR^2R^{2a}$, and $SO_2NR^2R^{2a}$;

R^7, at each occurrence, is selected from H, OH, C_{1-3} alkyl, C_{1-3} alkylcarbonyl, C_{1-3} alkoxy, C_{1-4} alkoxycarbonyl, benzyl, phenoxy, phenoxycarbonyl, benzylcarbonyl, C_{1-4} alkylcarbonyloxy C_{1-4} alkoxycarbonyl, phenylcarbonyloxy C_{1-4} alkoxycarbonyl, C_{1-6} alkylaminocarbonyl, phenylaminocarbonyl, and phenyl C_{1-4} alkoxycarbonyl;

R^8, at each occurrence, is selected from H, CH_3, and benzyl; and,

alternatively, R^7 and R^8 combine to form a morpholino group;

R^9, at each occurrence, is selected from H, CH_3, and benzyl.

18. A compound according to Claim 17, wherein the compound is of formulae Ib and Ic:

R^{1a} is absent or is selected from H, CH_3, CH_2CH_3, Cl, F, CF_3, OCH_3, NR^2R^{2a}, $S(O)_pR^{2b}$, $C(O)NR^2R^{2a}$, $CH_2S(O)_pR^{2b}$, $CH_2NR^2S(O)_pR^{2b}$, $C(O)R^{2c}$, $CH_2C(O)R^{2c}$, and $SO_2NR^2R^{2a}$;

R^{1b} is absent or is selected from H, CH_3, CH_2CH_3, Cl, F, CF_3, OCH_3, NR^2R^{2a}, $S(O)_pR^{2b}$, $C(O)NR^2R^{2a}$, $CH_2S(O)_pR^{2b}$, $CH_2NR^2S(O)_pR^{2b}$, $C(O)R^{2b}$, $CH_2C(O)R^{2b}$, and $SO_2NR^2R^{2a}$;

A is selected from one of the following carbocyclic and heterocyclic systems which are substituted with 0-2 R^4;
phenyl, pyridyl, and pyrimidyl;

B is selected from: Y and X-Y;

X is selected from -C(O)- and O;

Y is NR^2R^{2a}, provided that X-Y do not form a O-N bond;

alternatively, Y is selected from one of the following carbocyclic and heterocyclic systems which are substituted with 0-2 R^{4a};

phenyl, piperazinyl, pyridyl, pyrimidyl, morpholinyl, pyrrolidinyl, imidazolyl, and 1,2,3-triazolyl;

R^2, at each occurrence, is selected from H, CF_3, CH_3, benzyl, and phenyl;

R^{2a}, at each occurrence, is selected from H, CF_3, CH_3, benzyl, and phenyl;

R^{2b}, at each occurrence, is selected from CF_3, OCH_3, CH_3, benzyl, and phenyl;

R^{2c}, at each occurrence, is selected from CF_3, OH, OCH_3, CH_3, benzyl, and phenyl;

alternatively, R^2 and R^{2a} combine to form a ring system selected from pyrrolidinyl, piperazinyl and morpholino;

R^4, at each occurrence, is selected from Cl, F, CH_3, NR^2R^{2a}, and CF_3;

R^{4a}, at each occurrence, is selected from Cl, F, CH_3, $SO_2NR^2R^{2a}$, $S(O)_pR^5$, and CF_3; and,

R^5, at each occurrence, is selected from CF_3 and CH_3.

19. A compound according to Claim 1, wherein the compound is selected from the group:

3-(3-amidinophenyl)-4-[(2'-aminosulfonyl-[1,1']-biphen-4-yl)aminocarbonyl]-5-(hydroxymethyl)isoxazole;

3-(3-amidinophenyl)-4-[(2'-aminosulfonyl-[1,1']-biphen-4-yl)aminocarbonyl]isoxazole;

3-(3-amidinophenyl)-4-[(2'-methylsulfonyl-[1,1']-biphen-4-yl)aminocarbonyl]isoxazole;

3-(3-amidinophenyl)-4-[5-(2-aminosulfonyl)phenylpyrid-2-yl)aminocarbonyl]-5-(methoxymethyl)isoxazole;

3-(3-amidinophenyl)-4-[(2'-trifluoromethyl-[1,1']-biphen-4-yl)aminocarbonyl]isoxazole;

3-(3-amidinophenyl)-4-[(2'-aminosulfonyl-[1,1']-biphen-4-yl)aminocarbonyl]-5-(trifluoromethyl)isoxazole;

2-acetylamino-4-(3-amidinophenyl)-5-[(2'-aminosulfonyl-[1,1']-biphen-4-yl)aminocarbonyl]thiazole;

2-amino-4-(3-amidinophenyl)-5-[(2'-aminosulfonyl-[1,1']-biphen-4-yl)aminocarbonyl]thiazole;

2-methyl-4-(3-amidinophenyl)-5-[(2'-aminosulfonyl-[1,1']-biphen-4-yl)aminocarbonyl]thiazole;

5-(3-amidinophenyl)-4-[(2'-aminosulfonyl-[1,1']-biphen-4-yl)aminocarbonyl]oxazole;

3-(3-amidinophenyl)-4-[(2'-t-butylaminosulfonyl-[1,1']-biphen-4-yl)aminocarbonyl]isoxazole;

3-(3-amidinophenyl)-4-[(2'-aminosulfonyl-[1,1']-biphen-4-yl)aminocarbonyl]-5-(methoxymethyl)-isoxazole;

3-(3-amidinophenyl)-4-[(2'-t-butylaminosulfonyl-[1,1']-biphen-4-yl)aminocarbonyl]isoxazole;

3-(3-amidinophenyl)-4-[(2'-aminosulfonyl-[1,1']-biphen-4-yl)aminocarbonyl]-5-(methoxymethyl)isoxazole;

2-methyl-4-(3-amidinophenyl)-5-[(2'-trifluoromethyl-[1,1']-biphen-4-yl)aminocarbonyl]thiazole;

2-phenyl-4-(3-amidinophenyl)-5-[(2'-aminosulfonyl-[1,1']-biphen-4-yl)aminocarbonyl]thiazole;

3-(3-amidinophenyl)-4-[(3-fluoro-2'-methylsulfonyl-[1,1']-biphen-4-yl)aminocarbonyl]isoxazole;

3-(3-amidinophenyl)-4-[(2'-trifluoromethylthio-[1,1']-biphen-4-yl)aminocarbonyl]isoxazole;

3-(3-amidinophenyl)-5-amino-4-[(2'-aminosulfonyl-[1,1']-biphen-4-yl)aminocarbonyl]isoxazole;

2-(phenylamino)-4-(3-amidinophenyl)-5-[(2'-aminosulfonyl-[1,1']-biphen-4-yl)aminocarbonyl]thiazole;

2-(benzylamino)-4-(3-amidinophenyl)-5-[(2'-aminosulfonyl-[1,1']-biphen-4-yl)aminocarbonyl]thiazole;

2-(methylamino)-4-(3-amidinophenyl)-5-[(2'-aminosulfonyl-[1,1']-biphen-4-yl)aminocarbonyl]thiazole;

2-(methylamino)-4-(3-carboxamidophenyl)-5-[(2'-aminosulfonyl-[1,1']-biphen-4-yl)aminocarbonyl]thiazole;

2-methyl-4-(3-amidinophenyl)-5-[[5-(2'-aminosulfonylphenyl-1-yl)pyridin-2-yl]aminocarbonyl]thiazole;

2-methyl-4-(3-(carboxamido)phenyl)-5-[[5-(2'-aminosulfonylphenyl-1-yl)pyridin-2-yl]aminocarbonyl]thiazole;

2-(3-pyridyl)-4-(3-amidinophenyl)-5-[(2'-aminosulfonyl-[1,1']-biphen-4-yl)aminocarbonyl]thiazole;

2-(3-pyridyl)-4-(3-carboxamidophenyl)-5-[(2'-aminosulfonyl-[1,1']-biphen-4-yl)aminocarbonyl]thiazole;

2-chloro-4-(3-amidinophenyl)-5-[(2'-aminosulfonyl-[1,1']-biphen-4-yl)aminocarbonyl]thiazole;

2-chloro-4-(3-carboxamidophenyl)-5-[(2'-aminosulfonyl-[1,1']-biphen-4-yl)aminocarbonyl]thiazole;

2-chloro-4-(3-amidinophenyl)-5-[[5-(2'-aminosulfonylphenyl-1-yl)pyridin-2-yl]aminocarbonyl]thiazole;

2-chloro-4-(3-(carboxamido)phenyl)-5-[[5-(2'-aminosulfonylphenyl-1-yl)pyridin-2-yl]aminocarbonyl]thiazole;

2-hydroxy-4-(3-amidinophenyl)-5-[[5-(2'-aminosulfonylphenyl-1-yl)pyridin-2-yl]aminocarbonyl]thiazole;

2-chloro-4-(3-aminophenyl)-5-[(2'-aminosulfonyl-[1,1']-biphen-4-yl)aminocarbonyl]thiazole;

2-amino-4-[(3-amino-4-chloro)phenyl]-5-[(2'-aminosulfonyl-[1,1']-biphen-4-yl)aminocarbonyl]thiazole;

2-chloro-4-[(3-amino-4-chloro)phenyl]-5-[(2'-aminosulfonyl-[1,1']-biphen-4-yl)aminocarbonyl]thiazole; and,

2-amino-4-[(3-aminomethyl)phenyl]-5-[(2'-aminosulfonyl-[1,1']-biphen-4-yl)aminocarbonyl]thiazole;

and a pharmaceutically acceptable salt thereof.

20. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound according to Claim 1 or a pharmaceutically acceptable salt thereof.

21. A method for treating or preventing a thromboembolic disorder, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound according to Claim 1 or a pharmaceutically acceptable salt thereof.